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“Imagination is more important than knowledge. For knowledge is limited to all we now know 
and understand, while imagination embraces the entire world, and all there ever will be to 
know and understand.” 
 
(Albert Einstein) 
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ABSTRACT 
This master's degree in Pharmaceutical Engineering was developed at the Faculty of 
Pharmacy of the University of Lisbon (FFUL) in partnership with the Laboratório Edol - 
Produtos Farmacêuticos, S.A. 
This project is based on a strong innovative component, since the control of elemental 
impurities has only applied to oral, parenteral and inhalation pharmaceutical forms. 
Therefore, the main objective of this project is perform a risk assessment for the control of EI 
in ophthalmological drugs of chronic, acute and sporadic use. To do this, it was necessary to 
carry out a study, as detailed as possible, of the entire process and components involved in 
the production of the three drugs products, making it essential to collect all process, product 
and use parameters. 
After an in-depth knowledge of all those involved in the manufacturing process of each of the 
ophthalmological drugs under study, a Risk Assessment methodology was developed based 
on the principles of ICH Q3D. In this methodology the various calculation options available in 
the ICH Q3D are tested and the control of the levels of Impurities is performed using the 
Permitted Parental Daily Exposure made available in the ICH Q3D, since due to the lack of 
information, it was not possible to calculate the PDEs of the ophthalmic route. 
With this project, it was possible to conclude that EI is commonly present in the most materials 
that come in direct contact with the drug and may affect the drug's efficacy and the health of 
the patient. It was also possible to verify that the lack of data was the greatest condition in 
the accomplishment of the same one, since it was necessary to resort to data of bibliography 
that represent scenarios quite maximized but still l most of the sources of elemental impurities 
are considered negligible, since the levels presented are much lower than the CL. Therefore, 
the Risk Assessment approach is an adequate strategy to control EI in ophthalmic drug 
products.   
The goal of this project has been successfully achieved, and a risk assessment methodology 
for ophthalmic products is now available. 
 
 
 
Key words: Elemental impurities, Eye drops solution Determination of Elemental 
Impurities, Simulation, Risk Assessment  
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RESUMO  
Este projeto de mestrado em Engenharia Farmacêutica foi desenvolvido na Faculdade de 
Farmácia da Universidade de Lisboa (FFUL) em parceria com o Laboratório Edol - Produtos 
Farmacêuticos, S.A. 
As impurezas elementares são contaminantes que podem ser oriundos da adição intencional 
de catalisadores, na síntese da substância medicamentosa, ou podem surgir naturalmente 
devido à contaminação ambiental dos excipientes ou substância ativa que compõem a 
formulação do medicamento. 
As interações existentes entre os equipamento e todos os materiais que contactam 
diretamente com o produto durante a sua produção, incluindo os materiais de 
armazenamento, que por norma no caso de colírios são feitos de polímeros, são outro fator 
a ter em consideração numa avaliação de risco devido aos longos tempos de exposição do 
produto a estes materiais. Assim sendo, e sabendo que as impurezas elementares não 
oferecem qualquer benefício terapêutico e que por outro lado podem afetar negativamente 
o comportamento toxicológico do fármaco é extremamente importante controlar os seus 
níveis a fim de se garantir que estes se encontram dentro dos limites aceitáveis. O controlo 
das impurezas elementares era efetuado recorrendo ao método colorimétrico, no entanto, 
devido às suas limitações, e com o objetivo de se harmonizar os requerimentos técnicos 
para a regulação de impurezas elementares em produtos farmacêuticos de três regiões 
(Europa, Japão e Estados Unidos) a ICH iniciou, em 2009, a Q3D. Este documento 
classificou as impurezas elementares em 3 classes e estabeleceu os PDE para os 24 
elementos. No entanto, este guia apenas apresenta os PDE’s para as vias de administração 
oral, parentéricas e inalatórias, ficando por estabelecer para as restantes vias. Sugere ainda 
que o controlo das impurezas elementares seja efetuado recorrendo aos princípios descritos 
na ICH Q9 assim sendo, este projeto assenta numa forte componente inovadora, dado que 
o principal objetivo deste projeto é a realização de uma avaliação de risco para o controle 
de impurezas elementares em medicamentos oftalmológicos de uso crónico, agudo e 
excecional. Para que tal seja exequível, foi necessário efetuar-se um estudo, o mais 
detalhado possível, de todo o processo e intervenientes envolvidos na produção dos três 
medicamentos, tornando-se essencial a recolha de todos os parâmetros de processo, 
produto e utilização.  
Após um conhecimento aprofundado de todos os intervenientes no processo de fabrico de 
cada um dos medicamentos oftalmológicos em estudo, desenvolveu-se, baseada nos 
princípios da ICH Q3D, uma metodologia de Risk Assessment. Nesta metodologia são 
testadas as várias opções de cálculos disponibilizadas na ICH Q3D e o controle dos níveis 
de Impurezas é realizado recorrendo aos PDE’s parentéricos disponibilizados na ICH Q3D, 
dado que devido à inexistência de informação, não foi possível efetuar o cálculo dos PDE’s 
da via oftalmológica e a absorção medicamentosa nesta via é maioritariamente por via 
parentérica. A metodologia apresentada contempla 7 etapas: 
• Etapa 1 – Identificação das fontes de impurezas elementares – Nesta etapa é 
realizado um estudo aprofundado de todos os componentes que contactam 
diretamente com o produto durante a sua produção, pretende-se obter uma lista 
exaustiva de todos os intervenientes a fim de se obter uma perspetiva global dos 
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potenciais contaminantes do medicamento. Para que tal seja exequível, por norma 
recorre-se a um diagrama Ishikawa. 
 
• Etapa 2 – Avaliação da contribuição da substância ativa e excipientes para a 
presença de impurezas elementares no produto final – Após a identificação da 
substância ativa e respetivos excipientes, foi necessário obter informação relativa à 
presença de impurezas elementares nos mesmos. Assim sendo, contactou-se os 
respetivos fornecedores que, quando tinham a informação disponível, enviaram os 
respetivos dossiers com os elementos presentes nos seus produtos e as respetivas 
concentrações. No caso de inexistência de resposta foi decidido assumir o worst-
case scenario, isto é, que cada impureza assumiria a concentração permitida 
disponibilizada pela ICH Q3D. Após se obter esta triagem, ficou decidido quais os 
elementos a incluir nesta avaliação, nos casos em que o fornecedor não 
disponibilizou dados, assumiu-se que para esse produto as impurezas elementares 
não teriam sido intencionalmente adicionadas e por esse motivo a avaliação de risco 
foi realizada segundo as recomendações da ICHQ3D para elementos a serem 
considerados na avaliação de risco para a via de administração parentérica. De 
seguida comparou-se as concentrações de cada impureza elementar com as 
concentrações limite obtidas pelas opções de cálculo 1, 2A e 2B, disponibilizadas 
pela ICH Q3D. 
 
• Etapa 3 – Avaliação da contribuição do equipamento de fabrico para a presença de 
impurezas elementares no produto final – O equipamento que contacta diretamente 
com o produto durante toda a fase de produção, incluindo o embalamento, pode 
constituir sérios riscos para a presença de impurezas elementares. Assim sendo, foi 
efetuado um levantamento criterioso de todo o equipamento, para os 3 produtos em 
teste, com o objetivo de se obter a sua composição e assim entender quais os 
potenciais elementos contaminantes. Do contacto com os fornecedores apenas se 
obteve os certificados analíticos de qualidade, tendo sido necessário recorrer-se à 
pesquisa bibliográfica para se obter a constituição do aço inox. Em termos de 
avaliação de risco, optou-se por usar uma abordagem conservativa em que se 
assume que por cada lote de fabrico migra 0.5 g/metal para o produto final. Assim, a 
contribuição do equipamento para a presença de impurezas elementares foi 
realizada para o lote de fabrico mais pequeno, de entre os produtos em tese, com o 
objetivo de se obter o worst-case scenario. 
 
• Etapa 4 - Avaliação da contribuição dos filtros para a presença de impurezas 
elementares no produto final – Após o levantamento dos filtros utilizados durante o 
processo de fabrico contactou-se os fornecedores a fim de se obter os elementos 
presentes nos mesmo, dado que não se obteve resposta, recorreu-se à pesquisa 
bibliográfica para se estimar os elementos e as respetivas concentrações. Salienta-
se que as concentrações obtidas estão bastante sobrestimadas, pois as condições 
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onde são realizados os testes de extração são bastante mais agressivas que as 
próprias características do produto.  
 
• Etapa 5 - Avaliação da contribuição do sistema de tratamento de água para a 
presença de impurezas elementares no produto final – A água é o elemento mais 
comum na maioria das preparações farmacêuticas, especialmente nos colírios, e é 
facilmente contaminado. Assim sendo, foi realizado um estudo de todo o sistema de 
tratamento de água, permitindo identificar todos os materiais que contactam 
diretamente com a água. Após o contacto com os fornecedores verificou-se que a 
informação obtida era bastante escassa tendo sido necessário recorrer à pesquisa 
bibliográfica. 
 
• Etapa 6 - Avaliação da contribuição do sistema de acondicionamento para a 
presença de impurezas elementares no produto final – Os sistemas de 
acondicionamento são considerados uma das maiores fontes de impurezas 
elementares, dado que o tempo de residência do produto é bastante elevado. Tendo 
em conta este facto, é extremamente importante efetuar um levantamento do material 
que constitui este sistema. No caso dos produtos em teste estes apenas contactam 
com um tipo de polímero, tendo sido o próprio fornecedor a realizar os testes para a 
presença de impurezas elementares e a disponibilizá-lo.  
 
 
• Etapa 7 – Resumo da Avaliação de Risco – Nesta etapa foi decidido estudar-se 3 
cenários, para se obter uma perspetiva diferente das várias possibilidades em 
estudo. Esta etapa permite ao aplicante decidir se é necessário recorrer a ações de 
correção, recorrendo para isso aos princípios descritos na ICH Q3D.   
Com a implementação desta metodologia foi possível verificar, que embora os cenários em 
teste estejam bastante maximizados, que a análise de risco é uma abordagem perfeitamente 
adequada para a quantificação destes contaminantes, pois as concentrações obtidas são 
bastante abaixo das concentrações limite.  
A realização deste projeto científico permitiu ainda verificar que a ICH Q3D apresenta 
algumas limitações, nomeadamente ao nível das opções de cálculo disponibilizas, pois estas 
deveriam ter em consideração as vias de administração e a forma farmacêutica em estudo. 
Assim sendo, o objetivo deste projeto foi alcançado com sucesso, e uma metodologia de 
avaliação de risco para produtos oftalmológicos encontra-se agora disponível.  
 
Palavras-Chave: Impurezas Elementares, Colírios, Determinação de Impurezas 
Elementares, Simulação, Avaliação de Risco  
VIII 
 
AKNOWLEGEMENTS  
A realização deste projeto não seria possível sem o contributo de algumas pessoas, que 
deste modo, apoiaram e incentivaram tornado possível a concretização deste projeto 
científico. 
Em primeiro gostaria de agradecer ao professor Rui Loureiro da Faculdade de Faculdade de 
Farmácia da Universidade de Lisboa e orientador principal da minha tese, pelo apoio 
incondicional, pelo acompanhamento cuidado e por um esclarecimento mais abordado 
acerca do tema em estudo. 
Agradeço à Prof. Doutora Joana Marques Marto da Faculdade de Faculdade de Farmácia 
da Universidade de Lisboa e minha coorientadora, por todo o apoio e disponibilidade 
demonstrada durante a execução deste trabalho científico, pois sem para além de toda a 
ajuda prestada foi um grande elo de ligação com o Laboratório EDOL, Produtos 
Farmacêuticos SA. 
Ao Engenheiro Diogo Manata, por toda a disponibilidade prestada no esclarecimento de 
algumas questões técnicas cruciais ao desenvolvimento do meu projeto. 
Á Prof. Doutora Helena Margarida Marques da Faculdade de Faculdade de Farmácia da 
Universidade de Lisboa e à Doutora Sara Raposo Loreau Diretora do Controlo de Qualidade 
e I&D do Laboratório EDOL, Produtos Farmacêuticos SA, pelo apoio e por todas as 
sugestões proferidas.  
Agradeço ainda aos meus pais e avós, alicerces importantes na minha educação, e que sem 
eles nada disto seria possível. Obrigado pelo apoio e força dados para a concretização dos 
meus objetivos. Agradeço ainda aos meus irmãos e amigos por todo o apoio, incentivo e 
paciência durante a elaboração deste projeto científico, em especial à Ana Fernandes e à 
Patrícia Silva que foram grandes alicerces nos momentos mais complicados.   
 
 
 
 
 
 
 
 
IX 
 
List of Contents  
 
ABSTRACT ....................................................................................................................................... IV 
RESUMO ............................................................................................................................................. V 
AKNOWLEGEMENTS ................................................................................................................... VIII 
LIST OF FIGURES ......................................................................................................................... XIII 
LIST OF TABLES ........................................................................................................................... XIV 
CHAPTER 1 – Introduction .............................................................................................................1 
CHAPTER 2 – Literature Review ...................................................................................................2 
2.1 Regulation of Impurities .....................................................................................................2 
2.2 Impurities ..............................................................................................................................5 
2.3 Heavy metals to Elemental Impurities..............................................................................7 
2.4 Elemental Impurities ...........................................................................................................7 
2.4.1 Sources of Contamination ............................................................................... 8 
2.4.2 New methods used to determine EI in drug product......................................... 9 
2.5 . Quality Risk Management ............................................................................................ 11 
2.5.1 Risk Assessment process .............................................................................. 12 
2.5.2 Risk Control ................................................................................................... 13 
2.5.3 Risk Communication ...................................................................................... 15 
CHAPTER 3 – Materials and Methods ...................................................................................... 16 
3.1 Data and data processing ............................................................................................... 16 
3.2 Methodology for obtaining the PDE’s for the ophthalmic route ................................. 16 
3.3 Calculation the Concentration Limit (CL) to control the levels of EI in the Active 
Substance and Excipients that composes the drug product. .................................. 18 
3.3.1. Option 1: ....................................................................................................... 18 
3.3.2. Option 2A: ..................................................................................................... 19 
3.3.3. Option 2B: ..................................................................................................... 19 
3.3.4. Option 3: ....................................................................................................... 20 
3.4. Risk Assessment Process ............................................................................................ 20 
3.4.1. Step 1: Identification of sources of the EI: .................................................... 21 
3.4.2. Step 2: Evaluation of the contribution of the Active Substance and Excipients 
to the presence of EI in the final dur product: ................................................. 22 
3.4.3. Step 3: Evaluation of the contribution of the Manufacturing Equipment to the 
presence of EI in the final dur product: .......................................................... 23 
3.4.4. Step 4: Evaluation of the contribution of the filters to the presence of EI in the 
final drug product: .......................................................................................... 24 
3.4.5. Step 5: Evaluation of the contribution of the Water Treatment System to the 
presence of EI in the final drug product:......................................................... 24 
3.4.6. Step 6: Evaluation of the contribution of the Container Closure System to the 
presence of EI in the final drug product:......................................................... 24 
X 
 
3.4.7. Step 7: Summary of the Risk Assessment: ................................................... 25 
CHAPTER 4 – Results and Discussion of Results ................................................................ 26 
4.1. Drug product 1 ................................................................................................................ 26 
4.1.1. Drug product presentation ............................................................................. 26 
4.1.2. Information about components of the drug product to be included in the Risk 
Assessment ................................................................................................... 28 
4.1.3. Sources of Contamination ............................................................................. 31 
4.1.4. Elements included in Risk Assessment ......................................................... 32 
4.1.5. Risk Assessment to Active Substance and Excipients .................................. 32 
4.2. Drug product 2 ................................................................................................................ 36 
4.2.1. Drug product presentation ............................................................................. 36 
4.2.2. Information about components of the drug product to be included in the Risk 
Assessment ................................................................................................... 38 
4.2.3. Sources of Contamination ............................................................................. 40 
4.2.4. Elements included in Risk Assessment ......................................................... 40 
4.2.5. Risk Assessment to Active Substance and Excipients .................................. 41 
4.3. Drug Product 3 ............................................................................................................... 45 
4.3.1. Drug product presentation ............................................................................. 45 
4.3.2. Information about components of the drug product to be included in the Risk 
Assessment ................................................................................................... 47 
4.3.3. Sources of Contamination ............................................................................. 49 
4.3.4. Elements included in Risk Assessment ......................................................... 49 
4.3.5. Risk Assessment to Active Substance and Excipients .................................. 50 
4.3.6. Risk Assessment to Manufacturing Equipment ............................................. 55 
4.3.7. Risk Assessment to Filters ............................................................................ 57 
4.3.8. Risk Assessment to Water treatment system ................................................ 59 
4.3.9. Risk Assessment to Container Closure System ............................................ 62 
4.3.10. Summary of the Risk Assessment ......................................................... 63 
4.3.10.1. Summary of Risk Assessment for drug product 1. ................................ 64 
4.3.10.2. Summary of Risk Assessment for drug product 2. ................................ 69 
4.3.10.3. Summary of Risk Assessment for drug product 3. ................................ 74 
4.3.11. Discussion of Results ............................................................................. 79 
CHAPTER 5 – Conclusion .............................................................................................................. 81 
CHAPTER 6 – Further Considerations ......................................................................................... 82 
References ........................................................................................................................................ 83 
Appendix 1 ........................................................................................................................................ 86 
Appendix 2 – Risk Assessment Methodology ............................................................................. 87 
 
 
XI 
 
 
 
 
LIST OF ABREVIATIONS  
 
AAS Atomic Absorption Spectrometry  
Ag Silver 
Al Aluminium 
API Active Pharmaceutical Ingredient 
As Arsenic 
Au Gold 
B Boron 
Ba Barium 
Bi Bismuth 
BP British Pharmacopeia 
Ca Calcium 
Cd Cadmium 
CL Concentration Limit 
Co Cobalt 
Cr Chromium 
EI Elemental Impurities 
EMA European Medicines Agency 
Fe Iron 
GR-AAS Atomic Absorption Spectrometry including graphic furnace 
HDPE High Density Polyethylene 
Hg Mercury 
ICH International Conference on Harmonization 
ICP Inductively Coupled Plasma 
ICP-MS Inductively coupled plasma mass spectrometry 
ICP-OES/AES Inductively Coupled Plasma Optical Emission Spectrometry 
Ir Iridium 
JP 
Japanese Pharmacopoeia 
 
K Potassium 
LDPE Low Density Polyethylene 
Li Lithium 
LO(A)EL 
Low-Observed-Effect Level 
 
MDD Maximum Daily Dose 
XII 
 
Mg Magnesium 
Mn Mn 
Mo Molybdenum 
Na Sodium 
Ni Nickel 
NO(A)EL Non-Observed-Effect Level 
Os Osmium 
Pb Lead 
Pd Palladium 
PDE Permitted Daily Exposure 
Ph.Eur European Pharmacopoeia 
Pt Platinum 
QRM Quality Risk Management  
Rh Rhodium 
Ru Ruthenium 
Sb Antimony 
Se Selenium 
Sn Tin 
Tl Thallium 
USP United States Pharmacopoeia 
V Vanadium 
W Tungsten 
Zn Zinc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XIII 
 
 
 
 
LIST OF FIGURES  
Figure 1. EMA classification of EI. Adapted (9). .................................................................. 2 
Figure 2. Potential Sources of metallic impurities during the production process of 
pharmaceuticals. Adapted (28)............................................................................................ 8 
Figure 3. Articles published from 2005 to 2015 (up to October 2015) regarding to the use of 
inductively coupled plasma (ICP)-based and atomic absorption spectrometry (AAS) methods 
for the determination of elements elemental impurities in pharmaceutical products. Data 
received from: (24). ............................................................................................................10 
Figure 4. Overview of a typical quality management process (34). ....................................12 
Figure 5. Risk Assessment process...................................................................................13 
Figure 6. Hierarchy of Controls (40)...................................................................................14 
Figure 7. Simplifying methodology to implement the ICH Q3D. .........................................21 
Figure 8. Fishbone diagram showing risk assessment of inclusion of the EI in production of 
a drug product and potential sources and the overall contribution of the EI to the drug product 
(adapted by ICH Q3D guideline (2)). ..................................................................................22 
Figure 9. Methodology to identify the elements included in the manufacturing. .................23 
Figure 10. Potential sources of Elemental Impurities in drug product 1. .............................31 
Figure 12. Potential sources of Elemental Impurities in drug product 2. .............................40 
Figure 14. Potential sources of Elemental Impurities in drug product 3. .............................49 
Figure 15. Diagram of the water treatment system. ...........................................................59 
 
 
 
 
 
 
XIV 
 
LIST OF TABLES  
 
Table 1. ICH Q3D Classification of elemental Impurities and the need for Risk Assessment 
considering the route of administration. Adapted from (2). .................................................. 4 
Table 2. Parental Permitted Daily Exposures for Elemental Impurities. Data revived from (2).
...........................................................................................................................................18 
Table 3. Permitted Concentration of EI, adapted from (2). .................................................23 
Table 4. Model table that allows to obtain the Summary of the Risk Assessment. .............25 
Table 5.Composition of drug product 1. .............................................................................27 
Table 6. Analytical data of elemental impurities in excipient 2, provided by Novo Nordisk 
Pharmatech........................................................................................................................29 
Table 7.Analytical data of elemental impurities in Excipient 5, provided by Merck Millipore.
...........................................................................................................................................30 
Table 8. Elements considered in elemental impurities Risk Assessment for drug product 1.
...........................................................................................................................................32 
Table 9. Predicted Elemental impurities level in drug product 1 take in consideration the 
option 1 and assuming one daily amount of drug product of 3 g/day. .................................33 
Table 10. Predicted Elemental impurities level in drug product 1 take in consideration the 
option 1 and assuming one daily amount of drug product of 5 g/day. .................................33 
Table 11. Predicted Elemental impurities level in drug product 1 take in consideration the 
option 1 and assuming one daily amount of drug product of 10 g/day. ...............................34 
Table 12. Predicted Elemental impurities level in drug product 1 take in consideration the 
option 2A. ...........................................................................................................................35 
Table 13. Predicted Elemental impurities level take in consideration the option 2B............36 
Table 14. Qualitative/quantitative composition of drug product 2. ......................................37 
Table 15. Elements considered in elemental impurities Risk Assessment for drug product 2.
...........................................................................................................................................41 
Table 16. Predicted Elemental impurities level in drug product 2 take in consideration the 
option 1 and assuming one daily amount of drug product of 3 g/day. .................................42 
Table 17.Predicted Elemental impurities level in drug product 2 take in consideration the 
option 1 and assuming one daily amount of drug product of 5 g/day. .................................42 
Table 18. Predicted Elemental impurities level in drug product 2 take in consideration the 
option 1 and assuming one daily amount of drug product of 10 g/day. ...............................43 
XV 
 
Table 19.Predicted Elemental impurities level in drug product 2 take in consideration the 
option 2A. ...........................................................................................................................44 
Table 20. Predicted Elemental impurities level of drug product 2 take in consideration the 
option 2B. ...........................................................................................................................45 
Table 21. Composition of drug product 3 per bottle with 5 ml of solution. ...........................46 
Table 22. Analytical data of elemental impurities in API 3, provided by Química Sintética, 
S.A. ....................................................................................................................................47 
Table 23. Elements considered in elemental impurities Risk Assessment for drug product 3.
...........................................................................................................................................50 
Table 24. Predicted Elemental impurities level in drug product 3 take in consideration the 
option 1 and assuming one daily amount of drug product of 3 g/day. .................................51 
Table 25. Predicted Elemental impurities level in drug product 3 take in consideration the 
option 1 and assuming one daily amount of drug product of 5 g/day. .................................51 
Table 26. Predicted Elemental impurities level in drug product 3 take in consideration the 
option 1 and assuming one daily amount of drug product of 10 g/day. ...............................52 
Table 27. Predicted Elemental impurities level in drug product 3 take in consideration the 
option 2A. ...........................................................................................................................53 
Table 28. Predicted Elemental impurities level in drug product 3 take in consideration the 
option 2B. ...........................................................................................................................54 
Table 29. Composition of stainless steel grades 304, 316 and 316L. The values are present 
in percentage and represent the worst-case scenario. .......................................................55 
Table 30. Main equipment that directly contact with the three drugs products during their 
manufacturing. ...................................................................................................................55 
Table 31. Stainless steel 316L EI contribution in the finished drug product considering 
material composition. .........................................................................................................57 
Table 32. Predicted EI levels from filters materials used in the manufacture train of the drug 
products, obtained through extraction. Concentrations are presented in µg/g. Data retrieved 
from reference (3)(57). .......................................................................................................58 
Table 33. Components of the water treatment system to be included in the Risk Assessment.
...........................................................................................................................................60 
Table 34.Predicted EI levels from water treatment system material. Concentrations are 
presented in µg/g. Data retrieved from reference (53)(57)(3). ............................................61 
Table 35. Predicted EI levels from LDPE bottle and dropper dispenser. Concentrations are 
presented in µg/g. ..............................................................................................................62 
Table 36. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
XVI 
 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A.
...........................................................................................................................................64 
Table 37. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B.
...........................................................................................................................................65 
Table 38. Conclusion summary of EI Risk Assessment assuming the contribution of Active 
Substance and Excipients given by option 2A and all contribution given by all components 
of the Risk Assessment against the Control Threshold for each identified elemental impurity.
...........................................................................................................................................66 
Table 39.  Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. ..............................................................................................67 
Table 40. Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. ..............................................................................................68 
Table 41. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A.
...........................................................................................................................................69 
Table 42. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B.
...........................................................................................................................................70 
Table 43. Conclusion summary of EI Risk Assessment assuming the contribution of Active 
Substance and Excipients given by option 2A and all contribution given by all components 
of the Risk Assessment against the Control Threshold for each identified elemental impurity.
...........................................................................................................................................71 
Table 44. Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. ..............................................................................................72 
Table 45. Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. ..............................................................................................73 
Table 46. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A.
...........................................................................................................................................74 
Table 47. Conclusion summary of EI Risk Assessment assuming the highest value of each 
element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B.
...........................................................................................................................................75 
XVII 
 
Table 48. Conclusion summary of EI Risk Assessment assuming the contribution of Active 
Substance and Excipients given by option 2A and all contribution given by all components 
of the Risk Assessment against the Control Threshold for each identified elemental impurity.
...........................................................................................................................................76 
Table 49.Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. ..............................................................................................77 
Table 50. Conclusion summary of EI Risk Assessment obtained only by the contribution of 
Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. ..............................................................................................78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1 – Introduction  
Elemental impurities (EI) are external entities to the drug product that may arise from a variety 
of sources. They can be added during the production of raw material, occur naturally by 
environmental contamination or result from contamination by the equipment and packaging 
systems. Because they have no therapeutic benefit and are associated with drug safety and 
efficacy problems, they should be controlled (1–3). 
The implementation of the ICH Q3D guideline, which establishes the permitted daily exposure 
(PDE) of each element for the oral, inhalation and parenteral routes, has led the 
pharmaceutical industry to focus on this theme, suggesting the control of these impurities (2,4). 
The objective of this project is to realize a Risk Assessment to implement this guideline to 
three products for ophthalmologic application and for chronic, acute and sporadic use, thus 
making it necessary to obtain an EI control methodology for the respective route of 
administration, to obtain the maximum level of elemental impurities in products (2). 
This project is divided in 6 chapters, the next chapter – LITERATURE OVERVIEW - has the 
purpose of giving the background required to understand the issues addressed in the later 
chapters. Therefore, the focus is mainly on EI and its regulation, and on the principles of 
Quality Risk Management (QRM). Following this, the chapter – MATERIALS AND METHODS 
– are described the materials and methods used to perform the experimental procedures 
related to the performance of the risk assessment are described. This chapter is focus on 
data processing, methodology for obtaining the PDE’s for the ophthalmic route, on options 
for control the levels of EI in active substance and excipients and finally in the methodology 
proposed for the implementation of the Risk Assessment. 
In chapter – RESULTS AND DISCUSSION OF RESULTS - presents the results obtained for 
the three products applying in a detailed way the methodology developed. These results are 
duly discussed during this chapter.  Finally, in Chapter – CONCLUSIONS -, the conclusions 
reached in this study are presented and on Chapter – FURTHER CONSIDERATIONS – are 
given future work perspectives, allowing the continuity of the work presented here. 
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CHAPTER 2 – Literature Review  
 
 
2.1 Regulation of Impurities  
The impurities in drug products often possess unwanted pharmacological–toxicological 
effects and do not provide any therapeutic benefit to the patient, their levels in the drug 
product should be controlled within acceptable limits (5)(6). 
In 1998, the European Medicines Agency (EMA), initiate the development of a guideline on 
residual catalysts in pharmaceuticals. The goal of this guidance is to establish limits for the 
control of 14 metal catalyst or metal reagents on toxicological safety assessment (7)(8). In 
2008, The EMA Guideline on Specification Limits for Residues of Metal Catalysts or Metal 
Reagents was officially implemented for new drug products. This guidance introduces the 
principle of the mass-based PDEs to establish permissible exposures in drug products rather 
than concentration limits in drug product. The PDEs in this guideline were based on 
assessments of toxicological data on individual metals (7).  
The EMA guideline clusters the 14 metal residues into three classes. Metals with significant 
toxicity, including human carcinogens, are placed in Class 1. This class are further subdivided 
into three subclasses called 1A, 1B and 1C. The class 1A include Platinum (Pt) and Palladium 
(Pd). Iridium (Ir), Osmium (Os), Rhodium (Rh) and Ruthenium (Ru) elements are placed in 
Class 1B. Class C elements are Molybdenum (Mo), Nickel (Ni), Chromium (Cr) and 
Vanadium (V). In Class 2 are placed metals with a low safety concern and which includes 
Cupper (Cu) and Manganese (Mn). Metals with no significant toxicity are grouped in Class 3. 
This class include Iron (Fe) and Zinc (Zn) (9). Figure 1 indicates classification of elements by 
EMA. 
 
 
Figure 1. EMA classification of EI. Adapted (9). 
EMA 
Classification
Class 1
Class 1A
(Pt and Pb)
Class 1B 
(Ir, Rh, Ru and 
Os)
Class 1C
(Cr, Ni, v and 
Mo)
Class 2
(Cu and Mn)
Class 3 
(Fe and Zn)
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Later in 2008, the USP proposed introduce two new chapters, chapter <232>, which would 
establish safety based limits on elemental impurities in pharmaceutical products, and <233> 
which would establish appropriate criteria in methods for elemental analysis, to replace the 
old colorimetric method <231> These chapters are official implemented in February 2013 (7).    
In 2009, with the scope of harmonizing technical requirements for elemental impurities in 
pharmaceutical products across three regions (Europe, Japan, and United States), the 
International Conference on Harmonization (ICH) initiated the Q3D expert working group. 
This working group, like in EMA guidance and USP chapters, try to set maximum PDE’s for 
elemental impurities in pharmaceutical products based on assessment of existing 
toxicological data for oral, parenteral and inhalation routes of administration. In June 2013, 
ICH Q3D reached step 2 and was published for a public review. The step 4 reaches in 
November 2014 and the USP Expert Panel on Elemental Impurities align Chapters <232> 
and <233> with Q3D (7).  
This council group propose classify 24 elemental impurities in three classes, based on their 
toxicity (PDE) and likelihood of occurrence in the drug product for inhalation, parenthetic and 
oral route. The probability of occurrence of each EI depends on factors such as: likelihood of 
use in pharmaceutical process, probability of being a co-isolated impurity with other elemental 
impurities in materials used in pharmaceutical process, and the observed natural abundance 
and environmental distribution of the element (2)(6). The elements are dived in three classes 
and two subclasses (Table 1).  The class 1 includes elements that are human toxicants and 
recommend evaluate them during the risk assessment. Their presence normally comes from 
used materials, such as mined excipients. Because your toxicity, the use of this elements 
needs to be limited or excludes in the manufacture of pharmaceuticals. In Class 2, the 
probably of occurrence the impurities in drug product are subdivided in Class 2A, 2B and 2C. 
The elements in Class 2A have more probably of occurrence in drug product than Class 2B 
elements, for this reason, these elements should be included in the risk assessment while 
Class 2B elements need not to be considered during the risk assessment, because they have 
low potential to be co-isolated with other materials. In the Class 3, are included the elements 
with low toxicity but they may require consideration for the risk assessment for inhalations 
and parenteral routes (2).  
This guidance still suggests some other elemental impurities, but because their low inherent 
potential toxicity and/or differences in regional regulations the PDEs are not established. The 
elements considered are: Aluminium (Al), Boron (B), Calcium (Ca), Iron (Fe), Potassium (K), 
Magnesium (Mg), Manganese (Mn), Sodium (Na), Tungsten (W) and, Zinc (Zn) (2)(6).  
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Table 1. ICH Q3D Classification of elemental Impurities and the need for Risk Assessment considering the route of 
administration. Adapted from (2). 
Class Elements Characteristics 
Risk Assessment 
If 
intentionally 
added (all 
routes) 
If not intentionally added 
Oral Parental Inhalation 
1 
Arsenic (As), Cadmium 
(Cd), Mercury (Hg), and 
Lead (Pb) 
Toxic elements that have 
limited or no use in the 
manufacture of 
pharmaceuticals, require risk 
assessment across all 
potential sources of EI and 
routes of administration. 
Yes Yes Yes Yes 
2A 
Cobalt (Co), Nickel (Ni), 
and Vanadium (V) 
High probability of occurrence 
in drug product, require risk 
assessment across all 
potential sources of EI and 
routes of administration. 
Yes Yes Yes Yes 
2B 
Silver (Ag), Gold (Au), 
Iridium (Ir), Osmium 
(Os), Palladium (Pd), 
Platinum (Pt), Rhodium 
(Rh), Ruthenium (Ru), 
Selenium (Se), and 
Thallium (Tl) 
Reduced probability of 
occurrence in drug product, 
excluded from the risk 
assessment unless they are 
intentionally added during the 
manufacture of drug product. 
Yes No No No 
3 
Barium (Ba), Chromium 
(Cr), Lithium (Li), 
Molybdenum (Mo), 
Antimony (Sb), and Tin 
(Sn). 
Low toxicities by the oral route 
of administration but may 
require consideration in the 
risk assessment for inhalation 
and parental routes. 
Yes No 
Yes, for Cu, 
Li, and Sb, 
no for Ba, 
Cr, Mo, and 
Sn 
Yes 
 
This guidance also suggests that EI in the drug should be controlled using the principles of 
Quality Risk Management, described in ICH Q9: “Quality Risk Management”. With this 
approach, the applicant can identify/analyse the risk, evaluate (compare levels with the 
PDE’s) and controls as required (2). But  this guidance does not provide any specific tool to 
perform this(2).   
The ICH guideline also provides a number of specific control options, to ensure that the 
concentration of elemental impurities in drug product or their components not exceed the 
PDEs. Option 1: Common permitted concentration limits of elements across drug product 
components for drug products with daily intakes of ≤10 g, providing a simplified approach to 
the PDE calculations. The option assumes that elemental impurities identified in the risk 
assessment (the target elements) are present in all components of the drug product (2). 
Option 2a: As per Option 1, except that the calculation is modified to include the specific 
product dose (2). 
Option 2b: Permitted concentration limits of elements across drug product component 
materials for a product with a specified daily intake. This option allows the applicant to 
establish limits in terms of permitted concentrations for each individual component based on 
the distribution of elements in the components, i.e., it permits higher concentrations of specific 
elements in some components provided that for each element the total amount of the 
elemental impurity in the final drug product does not exceed the permitted limit (2). 
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Option 3: Finished Product Analysis. The concentration of each element can be measured 
in the drug product (2). 
This guideline covers all elemental impurities, including those arising from natural sources 
and/or process impurities. In contrast, the earlier EMA guideline specifically focused on metal 
catalysts / metal reagents. 
The ICH Q3D Step 5 has been effect for new marketing authorisations since June 2016 and 
for existing authorised medicinal products since 2017 (10). The new USP General Chapters 
USP<232> ‘Elemental Impurities – Limits’, USP<233> ‘Elemental Impurities – Procedures’ 
and USP<2232> ‘Elemental Contaminants in Dietary Supplements has implemented in 1 
January 2018 (11)(10). 
 
 
2.2 Impurities 
According to ICH, an impurity in a drug substance is defined as “Any component of the drug 
product which is not the chemical entity defined as the drug substance or an excipient in the 
drug product” (ICH Q6A: Specifications) (12). In pharmaceutical world, an impurity are 
considered an external compound besides drug substance, or excipients, which arise out of 
synthesis or the unwanted chemicals that remains with the Active Pharmaceutical Ingredient 
(API) (13). 
Because pharmaceutical impurities are also referred to as “drug-related substances” they 
can arise from a variety of origins including starting materials, reaction by products generated 
during synthesis of drug substances, intermediates, degradation products formed during the 
formulation manufacture process and/or storage of formulated products, reagents, ligands 
and catalysts (14)(15). However, impurities can have safety and efficacy implications and are 
therefore the subject of considerable attention by both the manufacturer (industry) and 
regulatory (15). 
The safety of a drug product, or a dosage form, depends not only on the toxicological 
properties of the drug substance but also on the properties of those pharmaceutical impurities 
(14). The presence of impurities in pharmaceuticals, even in small amounts, is a concern, not 
only because some contaminants are inherently toxic, but because they may adversely affect 
the drug stability, efficacy and, self-life of the drug product, or may cause unwanted side-
effects (16)(17)(18).  
While the use of pharmaceuticals is always a balance of risks and benefits, the same is not 
true for impurities in pharmaceuticals, because impurities convey only risk and not have any 
therapeutic benefit to the patient, they are expected to be known and rigorously managed 
(19)(3). Monitor and control of impurities generally gives assurance of the quality and safety of 
a drug, but the control of pharmaceutical impurities are considerate a critical and challenging 
issue by pharmaceutical industry and regulatory agencies, because they try to create norms 
to assure that the level drug impurities does not reach high risk values (5)(20)(19).  
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Impurities in drug product can be dived in two types: Impurities associated with the API and 
Impurities formed during the formulation and/or aging or that are related to the formulated 
forms (17).  
The impurities associated with the API can be classified in three categories and different 
names can be adopted to classify these impurities, but according ICH guidelines, impurities 
can be classified in organic, inorganic and residual solvents (17)(13)(16).  
Organic impurities are commonly found in API’s and can arise during the manufacturing 
processes, including synthesis steps, and/or packing materials (16)(21)(22). They may be 
identified or unidentified, volatile or non-volatile (17). This type of impurities can be called 
“process and drug related” and can include: (21)(22)  
• Starting materials or intermediates 
• By-products of the synthesis:  
• Degradation products 
• Material using during the synthesis like reagents, ligands and catalysts (21)(22).   
Inorganic impurities are associated to manufacturing process and normally they are known 
and identified (16)(21). They can include:  
• Reagents, ligands, and catalysts 
• Heavy metals 
• Inorganic salts 
• Other materials like filters aids and charcoal (16)(21)(22). 
Residual solvents are organic volatile chemicals used in the manufacturing process of drug 
substances or excipients, or generated during the production (16). Normally this type of 
impurity can’t be totally removed by practical manufacturing techniques (21). The residual 
solvents are classified into three classes, depending on the level of risk they present to 
human health (16): 
• Class 1 solvents: Identifying with human carcinogens, strongly suspect human 
carcinogens, and environmental hazards. This class is to be avoided. 
• Class 2 solvents: Include non-genotoxic animal carcinogens or possible causative 
agents of other irreversible toxicity. Solvents suspected of other significant but 
reversible toxicities. The use of this solvents is to be limited. 
• Class 3 solvents: Solvents with low toxicity to human health (21). 
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2.3 Heavy metals to Elemental Impurities  
Heavy metals are natural compounds of the Earth’s crust and they cannot be degraded or 
destroyed. This components can enter in human body via food, drinking water, cigarettes and 
air (23).  But, in the past, the term “Heavy Metals” was erroneously used in literature to refer a 
group of metals, metalloids, and some non-metals which had some toxicity and were 
associated to contamination of pharmaceuticals. This term has no basis connection with 
toxicological or chemical data and suggest that all compounds of the same element (organic 
and/or inorganic) have the same physical, chemical and toxicological properties, which is not 
true for the most elements. In addition, heavy metals refer to any metallic chemical element 
that has relatively high density and is toxic at low concentrations. For the most 
pharmacopoeias the term heavy metals are “metallic impurities that are coloured by 7 
sulphide ion, under the specified test conditions” but this designation is limited because this 
term include other elements and only a specific group of elements respond to this test, in 
addition some relevant elements with toxicological relevance are not covered by this test. To 
solve this problem, a new designation for the term heavy metals was created and the term 
IE comes as a new designation for this group of elements (24).  
 
 
2.4 Elemental Impurities 
Are defined as elements that are found in the environment and that can be used or introduced 
in the manufacture of drug substances or excipients (25)(8). This term is adopted an alternative 
to the ill-defined term heavy metals and include various transition metals and metalloids (26).  
This metallic impurities can be present in pharmaceuticals from several sources and via a 
number different means (27)(3). They can be present in the drug product by intentional addition 
in chemical synthesis (metal catalysts or metal reagents),or be present by as a contaminant 
resulting the interactions with the process equipment and piping, raw materials, water, the 
environment, cleaning solvents and storage systems that contact directly with the drug 
product (6)(26)(27)(28). 
The presence of this elemental (inorganic) impurities in finish drug products, even in small 
amounts, may influence the safety and efficacy of the drug product (17). Their levels in the 
drug product should be known and controlled with the acceptable limits, because these 
contaminates not provide any therapeutic benefit and pose some risk to the patient health 
due to toxicological effects (6). 
Some elements classified as EI, like zinc, copper, chromium, iron, and manganese are 
considerate to be essential to the human nutrition, as they play critical roles in the structures 
of proteins and the activities of enzymes, but only in trace and ultra-trace levels (5)(27)(29). On 
the other hand, some elements such arsenic, mercury and lead, are known to be quite toxic 
to human beings (5). According this, the level of elemental impurities in drug products should 
be managed, known and low (3).   
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2.4.1 Sources of Contamination  
Elemental Impurities can be present in final drug product by intentional addition of the 
elements in the production process, such reagents and catalysts or can result of the elements 
cannot completely removed from the API synthesis (2)(25). There are also other sources of 
contamination related to the materials used in equipment and all surfaces (generally metals) 
that directly contacts with API or drug product. The incorporation of elemental impurities in 
drug product may be related to phenomena such as corrosion extraction/leaching, or 
delamination, like it was verified in contamination by aluminium from glass, zinc from plastic 
and rubber materials used in container closure systems (24).  
The container closure system is another source of elemental impurities because the 
elemental entities present in the materials of construction of this systems, that contact directly 
with the drug product, may leach to the during the time that the drug product is in contact with 
the polymers, and these leached elemental impurities become elemental impurities in drug 
product (3).  
Water is another source of contamination of the drug product because it is widely used in 
many pharmaceutical process, from synthesis to the production of pharmaceutical dosage 
forms and if any problem related to the quality of this component are not detected this can 
contaminate the drug product. According this, and because these contaminations are very 
difficult to detect, it is very useful to choose an appropriate Water Treatment System. To 
control the level of contamination of the water, is strongly recommended to determine EI level 
in all pharmacopoeias (24). In Figure 2, are identified the potential sources of metallic 
impurities present in production process of pharmaceuticals.  
 
 
Figure 2. Potential Sources of metallic impurities during the production process of pharmaceuticals. Adapted (28). 
9 
 
Knowledge about the presence, level and “leachability” of elemental entities in polymers used 
in manufacturing  and packaging systems is relevant to understanding how manufacturing 
and packaging systems contribute to a drug product’s total elemental impurity burden (3).   
 
2.4.2 New methods used to determine EI in drug product  
The pharmaceutical industry is subject to a high level of regulation, leading to the 
development and manufacture of drugs controlled by government agencies through a set of 
laws and guidance documents. The main propose of regulations is to ensure quality, efficacy 
and safety of drugs (8). The world regulatory agencies require the control and monitoring of 
the toxic elements to acceptable levels in pharmaceutical industry (11).  
The acceptable levels of heavy metals in pharmaceuticals usually are defined by the 
regulatory agencies and controlled by limit tests. These limit tests are regulated by 
pharmacopoeias and permit ensure the absence that inorganic contaminants in drug 
products (5)(8). Due this, the USP, British Pharmacopoeia (BP), European Pharmacopoeia 
(Ph.Eur) and Japanese Pharmacopoeia (JP) have developed chapters to propose collective 
monitoring of total metal content in drugs and drugs substances (5)(8)(30). These 
pharmacopoeia methods include this elements: As, Cd, Cu, Sn, Sb, Pb, bismuth (Bi), Ag, Hg 
and Mo and the methodology is similar in all pharmacopoeias, involve the precipitation of 
metal sulfides from a weak acid media and the colours of metal sufides range from white to 
yellow, orange, brown and black, this precipitate is compared by visual comparison with a 10 
ppm lead sulphide reference standard (dark brown) (8)(30)(5). This test has been in place for 
over 100 years, and different names are used by pharmacopoeias to designate this method. 
In USP  this test is called Chapter <231>: Heavy Metals Analysis and Ph.Eur General Chapter 
2.4.8 Heavy metals (8)(27).  
This colorimetric method have some significant limitations, that including non-specific 
method, less sensitive, time consuming and less accurate (5): 
• Subjective and difficult visual exam of the sample solution compared to standard 
solution. 
• The result of this method is seldom reliable and reproductible, because the formation 
of the sulfides is affected by sample matrix and hence.   
• Only applied to elements that form coloured sulfide precipitates, applicable to ten 
elements (Pb, Hg, Bi, As, Sb, Sn, Cd, Ag, Cu and Mo). 
• Non-selective method, which means it cannot distinguish between elements with 
high and low toxicity. 
• Requires large sample amounts for low detection levels (for example a minimum of 
2 g sample is required for a detection limit of 10 ppm). 
• Time consuming and require many workers. 
• The sample preparation can be leading to the loss of volatiles elements, because it 
occurs in a furnace at 600 degrees. It is mean that the procedure does not provide 
real quantitative results. (example: mercury in solid samples is not recovered at all) 
(8)(9)(31). 
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According to the limitations of the old colorimetric method, the Ph.Eur, USP and ICH have 
introduced new changes in regulation of elemental (inorganic) impurities, motivating an 
increase of the interest of determination of elemental impurities in pharmaceutical products  
(2)(28)(24).   
With this new changes, the wet chemical and colorimetric test have been replaced with 
instrumental methods that provide specific, quantitative determination of individual elemental 
impurities in drug products and ingredients and new analytical methods are proposed (32). 
The USP replace the old method with Inductively Coupled Plasma Mass Spectrometry (ICP-
MS) and Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES/AES) and 
the Ph.Eur provides a several general chapters for the analysis of elemental impurities using 
the analytical methods Atomic Absorption Spectrometry (AAS) , including graphic furnace 
AAS (GF-AAS), Inductively Coupled Plasma – Atomic Emission Spectrometry (ICP-
OEA/AES) and Inductively Coupled Plasma – Mass Spectrometry (ICP-MS) (11)(8).   
Determination of EI by ICP-based methods in pharmaceuticals is increasing, like we can 
observe in Figure 3. This increasing may be justified by the multielemental capability of 
plasma-based instruments, especially when compared with absorption spectrometry (AAS) 
(24). 
 
Figure 3. Articles published from 2005 to 2015 (up to October 2015) regarding to the use of inductively coupled plasma 
(ICP)-based and atomic absorption spectrometry (AAS) methods for the determination of elements elemental 
impurities in pharmaceutical products. Data received from: (24). 
In Figure 3 it is possible to verify that from the year 2008 to the year 2009, the interest by the 
ICP methods had a great prospect because two important documents from EMA and USP, 
both published in 2008, that refer to the evaluation of elemental impurities certainly 
contributed to increase the interest of this techniques. These documents alerted the 
community to the importance of establishing limits of concentration for EI and given the ability 
of these equipment’s to carry out analyses of multielements, these techniques were 
considered a valid option in the determination of EI. In 2010, the USP and BP create two 
general chapters to determine EI in APIs and this chapters are published in 2012 in EP. In 
these pharmacopoeias, the use of spectrometry techniques, including ICP-MS and ICP-OES, 
is recommended (24).   
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The main advantages and limitations of using ICP methods are described, covering the 
applications reported in the literature mainly for active substance, raw materials, and 
pharmaceutical dosage forms (24). These advantages include: 
• Ability to identify and quantify all elements with exception of Aragon. 
• Suitable for all concentrations from ultra-trace levels to major components because 
many wavelengths of varied sensitivity are available for determination of any one 
element. 
• Detection limits are generally low for most elements with a typical range of 1-100 
g/L. 
• Perform multielemental analysis quite and rapidly, a complete multielemental 
analysis can be undertaken in a period as short as 30 seconds and consuming only 
0.5 ml of sample solution (33). 
 
2.5 . Quality Risk Management  
Quality Risk Management (QRM) is a systematic process for the assessment, control, 
communication and review of risks to the quality of the drug (medicinal) product across the 
product lifecycle (34)(35). QRM concept depends upon the understanding of terms ‘Quality’ and 
‘Risk’. The term Quality means “The degree to which a set of inherent properties of a product, 
system or process fulfils requirements” (ICH Q9) and as per ISO/IEC Guide 51, the term Risk 
means “The combination of the probability of occurrence of harm and the severity of that 
harm” (35). 
Quality Risk Management, as described in ICH Q9, can be used in a variety of activities 
including assessing options for the design of the manufacturing process, assessing quality 
attributes and manufacturing process parameters, and increasing the assurance of routinely 
producing batches of the intended quality (36). It can provide a proactive approach to 
identifying, scientifically evaluating and controlling potential risks to quality. It facilitates 
continual improvement of process performance and product quality throughout the product 
lifecycle (37).The QRM process involves: 
• Hazards (sources of harm) that can adversely influence drug quality characteristics. 
• Extent of harm. 
• Sub processes critical for quality (35).  
A model for QRM outlined in the diagram (Figure 4). Other models could be used (34). 
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Figure 4. Overview of a typical quality management process (34). 
 
 
2.5.1 Risk Assessment process 
Risk Assessment, according to the principals described in ICH Q9: Quality Risk Management, 
has a part of a quality Risk system (Figure 4) and consists of the identification of hazards 
and the analysis and evaluation of the Risk associated with exposure to those hazards. 
According this, Risk Assessment is an simple way to minimize the process Risk, which should 
include a multidisciplinary expertise group and to begin with this approach it is necessary to 
have an well-defined problem description (38)(34). To do this, there are three fundamental 
questions: 
• What can go wrong with the process? 
• How frequently occur? 
• What are the consequences? 
 
 
 
2.5.1.1 Steps of Risk Assessment process 
To start a Risk Assessment process, it is necessary to follow a set of steps that the ICH Q9 
guide suggests (Figure 5). The first step is Risk Identification that consists of identifying 
the hazards of the entire manufacturing process, referring to the Risk question or problem 
description. Essentially, identifying the hazards answers the question, "What can go wrong?". 
This is a brainstorming activity with the team. This activity should generate many known and 
potential failure modes. The goal is to make this list as exhaustive as possible. Since 
identifying all potential failures can be an enormous task when considering an entire 
manufacturing process, the process map generated during the initiation phase of the risk 
management process is a valuable tool to generate the logical breaks that organize and focus 
the brainstorming (34)(39).   
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The next step in the Risk Assessment is Risk Analysis. It is the qualitative or quantitative 
process of linking the likelihood of occurrence and severity of harms. The qualitative or 
quantitative estimation of severity or the consequence, and the likelihood and the ability to 
detect the failure, are determined during the risk analysis (34).  
The final step in the Risk Assessment is the Risk Evaluation. In this stage are compared the 
identified and analysed Risk against given risk criteria.  At this point, the risk assessment 
phase ends (34). 
 
 
 
 
 
 
The risk management process would continue through the steps of risk control, risk review 
and communication (Figure 4).  
 
2.5.2 Risk Control 
Risk control includes decision making to reduce and/or accept risks. The purpose of risk 
control is to reduce the risk to an acceptable level. The amount of effort used for risk control 
should be proportional to the significance of the risk. Decision makers might use different 
processes, including benefit-cost analysis, for understanding the optimal level of risk control 
(34). 
Risk control might focus on the following questions: 
• Is the risk above an acceptable level? 
• What can be done to reduce or eliminate risks? 
• What is the appropriate balance among benefits, risks and resources? 
• Are new risks introduced as a result of the identified risks being controlled? 
 
Risk reduction focuses on processes for mitigation or avoidance of quality risk when it 
exceeds a specified (acceptable) level (Figure 4). Risk reduction might include actions taken 
to mitigate the severity and probability of damage. Processes that improve the detectability 
of hazard and quality risks might also be used as part of a risk control approach. The 
implementation of risk reduction measures can introduce new risks into the system or 
increase the significance of other existing risks. Hence, it might be appropriate to revisit the 
risk assessment to identify and evaluate any possible change in risk after implementing a risk 
reduction process (34).  
Risk 
Identification 
Risk Analysis
Risk 
Evaluation 
Figure 5. Risk Assessment process. 
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Risk acceptance is a decision to accept risk (decided case by case assessment). Risk 
acceptance can be a formal decision to accept the minor risk or it can be a passive decision 
in which minor risks are not specified. For some types of harms, even the best quality risk 
management practices might not eliminate risk .In these circumstances, it might be necessary 
an appropriate quality risk management support and that quality risk is reduced to a specified 
(acceptable) level (34). 
In some industries, are widely used the Hierarchy of Controls (Figure 6) to minimize or 
eliminate exposure to hazards. The hazard controls in the hierarchy are, in order of 
decreasing effectiveness: 
• Elimination 
• Substitution  
• Engineering Controls  
• Administrative Controls 
• Personal protective equipment (40).  
 
Figure 6. Hierarchy of Controls (40). 
 
The idea behind this hierarchy is that the control methods at the top of graphic are potentially 
more effective and protective than those at the bottom. Following this hierarchy normally 
leads to the implementation of inherently safer systems (41). 
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2.5.3 Risk Communication 
Risk communication is the sharing of information about risk and risk management between 
the decision makers and others. Parties can communicate at any stage of the risk 
management process (Figure 4). The output/result of the quality risk management process 
should be appropriately communicated and documented (Figure 4). Communications might 
include those among interested parties; e.g., regulators and industry, industry and the patient, 
within a company, industry or regulatory authority, etc. The included information might relate 
to the existence, nature, form, probability, severity, acceptability, control, treatment, 
detectability or other aspects of risks to quality. Communication need not be carried out for 
each and every risk acceptance. Between the industry and regulatory authorities, 
communication concerning quality risk management decisions might be affected through 
existing channels as specified in regulations and guidance’s (34). 
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CHAPTER 3 – Materials and Methods  
 
3.1 Data and data processing  
In Risk Assessment, the data and their mode of treatment can influence the success of this 
approach. Due this, in this scientific project, the data collection was performed following two 
different approaches. To obtain information about the levels of EI present in the API and 
Excipients, used in the formulation of the drug product, a formulary was sent to the respective 
suppliers. In absence of a response it was decided assuming the worst-case scenario, that 
the presence of EI in the component was in the maximum concentration allowed for option 1. 
This scenario was derived for the remaining calculation options. In the case of the supplier 
does not perform the EI level tests for the required elements and considering the route of 
administration to be used, it was decided that the highest value of an element that the supplier 
has quantified was assumed.  
A complete risk analysis includes the identification of all materials that directly contact with 
drug product, including throughout the manufacture. This material can contribute significantly 
to the presence of EI in final drug product, in order to obtain the possible contribution, it was 
performed a bibliographic literature review, in absence of information from the supplier. It is 
important to note that in many of these extractable studies the conditions under which the 
tests are carried out more aggressive than the properties of the product. Thus, these tests 
can overestimate the presence of this elements. 
The lack of data and the worst-case scenario negatively influence the outcome of the Risk 
Assessment, since the results obtained can lead to this analysis for three scenarios. 
Therefore, the result of the Risk Assessment can be found in the green zone, an area that, 
even assuming the worst scenario, does not require control actions to be implemented. The 
results that are in the orange zone, are considered limiting because they are close to the 
zone that requires control actions. In the red zone are the results of Risk Assessment that 
exceed the maximum values of control. In this zone control actions are necessary, resorting 
to the principles described in ICH Q9.  
 
3.2 Methodology for obtaining the PDE’s for the ophthalmic route 
The Permitted Daily Exposure (PDE) gives the maximum permitted quantity of each element 
that may be contained in the maximum daily intake of a drug product. In this guidance, the 
PDE’s are considered the to be protective of public health for all patients populations (2). 
The ICH Q3D, only establishes the PDE’s for the Oral, Parenteral and Inhalation routes of 
administration, however the objective of this scientific work is to apply this guide to ophthalmic 
products. Thus, it is necessary to obtain the PDE’s of each elemental impurity for the ocular 
route of administration and to do this it is necessary to calculate the ophthalmologic PDE. To 
perform this approach is necessary to apply the Equation 1, were the NO(A)EL means Non-
Observed-Effect Level and F1, F2, F3, F4 and F5 represents the modifying factors. 
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𝑃𝐷𝐸 =  
𝑁𝑂(𝐴)𝐸𝐿×𝑀𝑎𝑠𝑠 𝐴𝑑𝑢𝑠𝑗𝑡𝑚𝑒𝑛𝑡
𝐹1×𝐹2×𝐹3×𝐹4×𝐹5
 (Eq. 1) 
 
F1 – A factor to account for extrapolation between species. 
F2 – A factor 10 to account for variability between individuals. 
F3 – A variable factor to account for toxicity studies of short-term exposure. 
F4 – A factor that may be applied in cases of severe toxicity.  
F5 – A variable factor that may be applied if the NO(A)EL was not established. 
Normally, the PDE is preferably derived from a NO(A)EL. If no NO(A)EL is obtained, the 
LO(A)EL, Lowest-Observed-Effect Level, may be used. Due the lack of information on 
bioavailability, it was not possible to conclude this procedure and the suggestion of this 
guidance, derivation of the PDE, was adopted (2).  
Given the complexity of the eye as an organ, demonstration of appropriate acceptance limits 
for elemental impurities derived from the ophthalmic route of administration is required. Thus, 
a specific assessment for elemental impurities exposure and derived risks was performed, 
with an aim to establish acceptance limits for ophthalmologic products. During this 
assessment the factors considered were the physiology and the performance of the tear-flow 
drainage system, the effect of excipients and bioavailability of the drug product on ocular and 
the ocular toxicological profile of the elemental impurities of interest.  
According to the ocular toxicological profile of the elements it is possible indicate that, unless 
the eye is exposed to excessive levels of particular elements, no local effects or visual 
impairments are expected. Given that, the major part of the applied dose is absorbed 
systemically through a non-productive absorption to the conjunctiva of the eye via the nasal 
mucosa by spillage from the conjunctival sac or loss through the puncta to the lacrimal 
drainage system. Therefore, it was decided that the Permitted Daily Exposures, for ocular 
route, in all of the three products included in this scientific work, assume the values provided 
in ICH Q3D for parenteral route. Due this, no local effects are expected at exposure levels 
below the parenteral PDE values, thus it was not necessary apply modification factors in 
parental PDE’s (42)(43).   
In view of the facts above mentioned, for the proposes of the Risk Assessment, the values of 
the Predicted Daily Exposure of each elemental impurity included on this evaluation are 
depicted in Table 2. 
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Table 2. Parental Permitted Daily Exposures for Elemental Impurities. Data revived from (2). 
Element Class Parental Concentration (µg/g) 
Cd 1 0.2 
Pb 1 0.5 
As 1 1.5 
Hg 1 0.3 
Co 2A 0.5 
V 2A 1 
Ni 2A 2 
Tl 2B 0.8 
Au 2B 10 
Pd 2B 1 
Ir 2B 1 
Os 2B 1 
Rh 2B 1 
Ru 2B 1 
Se 2B 8 
Ag 2B 1 
Pt 2B 1 
Li 2B 25 
Sb 3 9 
Ba 3 70 
Mo 3 150 
Cu 3 30 
Sn 3 60 
Cr 3 110 
 
 
3.3 Calculation the Concentration Limit (CL) to control the levels of EI in the Active Substance 
and Excipients that composes the drug product. 
To control the levels of EI originating from this drug components the ICH Q3D suggest the 
conversion of the PDE in a CL. The ICH Q3D suggests some acceptable approaches to 
establishing concentrations of EI in drug product or components that would assure that the 
drug product does not exceed the PDEs (2). The applicant may select any of these options 
and assure that the drug product does not exceed the PDE’s. In the case of this scientific 
project, we are test all options except the option 3 because it requires analysis on final drug 
product and it is not possible to realise. 
 
3.3.1. Option 1: 
This option is intended to be used in products with a daily intake (amount) of drug product of 
10 g or less. This approach assumes that the elemental impurities, identified during the Risk 
Assessment, are present in all components of the drug product and which must be tested by 
assuming a daily intake of 10 g, but in the case of the eye drops solution it was considered 
that this scenario was greatly overestimated (2). Thus, a bibliographic search in Infarmed 
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database was performed to identify which is the most common type of bottles used in 
packaging of eye drops solution.  
After analysing the results obtained (Appendix 1), it is possible to conclude that the most 
common types of bottle used in eye drops solution are 5 ml (37%), 10 ml (25%) and 3 ml 
(8%). According this, it was decided test this option assuming a daily intake of drug product 
of the 5, 10 and 3 g. Although daily intakes were readjusted, these scenarios are 
overestimated too, because it is assumed that a bottle of drug product is administrated per 
each day and according to the posology of an eye drops solution only a few drops are applied.   
With this option, the applicant can determine the maximum concentration in µg for each 
element, assuming these three daily intakes of drug product, using the Equation 2. 
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝐿𝑖𝑚𝑖𝑡 (µ𝑔/𝑔) =
𝑃𝐷𝐸 (µ𝑔/𝑑𝑎𝑦)
𝑑𝑎𝑖𝑙𝑦 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 (𝑔) 
 (Eq. 2) 
 
The CL is the maximum level of each EI in the drug product. To obtain acceptance by this 
option, the concentration obtained in drug product can’t be equal or more than the CL. 
 
 
3.3.2. Option 2A:  
 
This option is intended to be applied in a drug product with a specific daily intake. It is very 
similar to option 1, but in this case the daily intake of drug product is substituted by the MDD 
of drug product. This option allows, like the option 1, to obtain the CL for each EI, using the 
Equation 3. If all components in a drug product do not exceed the option 2A concentration 
for all target elements identified in the risk assessment, then all these components may be 
used in any proportion in the drug product (2). 
 
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝐿𝑖𝑚𝑖𝑡(µ𝑔/𝑔) =
𝑃𝐷𝐸 (µ𝑔/𝑑𝑎𝑦)
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝑑𝑎𝑖𝑙𝑦 𝑑𝑜𝑠𝑒 (𝑀𝐷𝐷) (𝑔/𝑑𝑎𝑦)
 (Eq. 3) 
 
3.3.3. Option 2B:  
The applicant can apply this option to obtain the permitted concentration limit of elements in 
individual components of a drug product with a specific daily intake (2).  
This option requires the determination of the maximum daily dose for each component and 
each element. To do this, we should multiply the predicted elemental impurities concentration 
value for the correspondent component daily dose (obtained by multiplying drug product MDD 
for the weight of the corresponding excipient) using the Equation 4 (2). 
 
𝑃𝐷𝐸 (µ𝑔/𝑑𝑎𝑦) ≥  ∑ 𝐶𝐾 .  𝑀𝑘 (Eq. 4) 
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K – Index for each of N components in the drug product 
Ck – Permitted concentration of the elemental impurity in component K (µg/g) 
Mk – Mass of component K in the maximum daily intake of the drug product (g) 
 
 
3.3.4. Option 3:  
This option is intended to be applied in finished product analysis. In this approach the 
concentration of each element may be measured in the final drug product. It is necessary to 
determine the maximum permitted concentration of elemental impurity and to do this the 
option 1 may be used with the maximum total dose of drug product. 
 
3.4. Risk Assessment Process 
Risk Assessment is a simple methodology to obtain an overview of the process and allows 
to make a plant to minimise the hazards of the manufacturing process and the damage 
associated (44). In the case of this scientific project, the methodology defined will allow 
obtaining information about the max level of each EI in the drug product and, consequently, 
if control measures are necessary. 
For the construction of a methodology that was reproducible and applied to other 
pharmaceutical forms, it was decided to follow the general considerations of ICH Q3D. These 
considerations are based on three steps, which in many cases can be carried out 
simultaneously (2). 
1. Identify the known and potential sources of EI. 
2. Evaluate the presence of each EI in all sources of EI and compare with the PDE. 
3. Summarize the Risk Assessment (2). 
The proposed methodology (Appendix 2) was constructed with the aim of simplifying the 
approach of ICH Q3D and was tested in three eye drops solutions. This methodology can be 
applied to any pharmaceutical form, as it has been attempted to be the least specific possible. 
This tool was created considering the manufacturing process involved, being possible to be 
readjusted whenever justified. Thus, our methodology is based on seven steps that present 
a set of decisions that influence the result of the Risk Assessment. Figure 7 shows, in a 
simplified way, the methodology implemented to carry out this Risk Assessment and each 
step of it will be discussed further in this chapter. 
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Drug product 
Study all 
manufactur
e process 
Step 1: Identification of sources of the EI
Step 2: Evaluation of the contribution of 
the Active Substance and Excipients to the 
presence of EI in the final drug product
Step 3: Evaluation of the contribution of 
the Manufacturing Equipment to the 
presence of EI in the final drug product
Step 4: Evaluation of the contribution of 
the Filters to the presence of EI in the final 
drug product
Step 5: Evaluation of the contribution of 
the Water Treatment System to the 
presence of EI in the final drug product
Step 6: Evaluation of the contribution of 
the Container Closure System to the 
presence of EI in the final drug product
Step 7: Summary of the Risk Assessment 
 
Figure 7. Simplifying methodology to implement the ICH Q3D. 
 
3.4.1. Step 1: Identification of sources of the EI: 
Identification the sources of elemental impurities is an extremely important step, as this 
will depend the success of the Risk Assessment. All sources should be exhaustively 
identified, specially all materials that directly contact with the drug product during the 
manufacture train and the origin of the Active Substance and Excipients used in the 
manufacture. These materials and components of drug products can have a greater 
contribution to the presence of EI in final drug product through any individual or any 
combination of these sources. This is schematically shown in a fishbone diagram (Figure 
8). 
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Figure 8. Fishbone diagram showing risk assessment of inclusion of the EI in production of a drug product and 
potential sources and the overall contribution of the EI to the drug product (adapted by ICH Q3D guideline (2)). 
All potential sources of contamination of identified elemental impurities should be included 
in the Risk Assessment to obtain a perspective of the contribution of each of them in the 
presence of impurities in the final product. This fishbone diagram was updated from the 
original diagram, since the methods and people were not included, and these can also 
contribute a lot to the appearance of impurities. 
 
3.4.2. Step 2: Evaluation of the contribution of the Active Substance and Excipients 
to the presence of EI in the final dur product: 
As previously mentioned in this scientific project, the outcome of a risk assessment depends 
on the data collected. Thus, for the evaluation of the contribution of the Active Substance and 
the Excipients the respective suppliers were contacted. When the suppliers provide the 
analytical results regarding the levels of EI in their products these results are used to estimate 
the presence of EI. On the other hand, when the manufacturer does not provide the analytical 
results regarding the levels of EI, the worst-case scenario was assumed, the permitted 
concentration of EI for each element included in this Risk Assessment (Table 3).  
The elements included in the Risk Assessment depends mainly of two factors, if they are 
intentionally added during their manufacture or if any element is leachable from any material 
that contacts with the Active Substance and Excipient. When no available information, was 
assumed that the EI are not intentionally added and the Risk Assessment are performed 
following the recommendations for elements to be considered in the Risk Assessment for 
Parental route of administration.  
After obtaining all elements to be considered in the Risk Assessment, and their respective 
concentrations, it is necessary to compare the sum of each EI contribution with the CL 
obtained by Eq. 2, 3 and 4. These equations belong, respectively, to the calculation options 
1, 2A and 2B. In this scientific work, these options were tested and if the contribution of each 
EI does not be equal or more than the CL, the applicant can validate this option and proceed 
with the Risk Assessment. 
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Table 3. Permitted Concentration of EI, adapted from (2). 
Element Class Parental Concentration (µg/g) 
Cd 1 0.2 
Pb 1 0.5 
As 1 1.5 
Hg 1 0.3 
Co 2A 0.5 
V 2A 1 
Ni 2A 2 
Tl 2B 0.8 
Au 2B 10 
Pd 2B 1 
Ir 2B 1 
Os 2B 1 
Rh 2B 1 
Ru 2B 1 
Se 2B 8 
Ag 2B 1 
Pt 2B 1 
Li 2B 25 
Sb 3 9 
Ba 3 70 
Mo 3 150 
Cu 3 30 
Sn 3 60 
Cr 3 110 
 
3.4.3. Step 3: Evaluation of the contribution of the Manufacturing Equipment to the 
presence of EI in the final dur product: 
To obtain the contribution of the manufacture equipment it is extremely important identify all 
equipment involved in production of the drug product. To select the equipment which offers 
more risk, the equipment that directly contacts with the drug product was identified. 
The composition of each manufacturing equipment was obtained after contact with the 
respective manufacturer of each equipment identified but they only provide analytical the 
quality certificates. In our case, the Risk Assessment is only performed for the stainless steel. 
To obtain the elements can be present in this material and their levels are performed a 
bibliographic search, and in Figure 9 are depicted the process used to identify the EI present 
in manufacturing equipment.    
 
Figure 9. Methodology to identify the elements included in the manufacturing. 
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To obtain this contribution was assumed a conservative approach, it was assumed 0.5 
g/metal leaches from each produced batch to the finished drug product, obtaining an extreme 
scenario. If the contribution of each EI is less than the PDE, they can be excluded of the Risk 
Assessment.  
 
3.4.4. Step 4: Evaluation of the contribution of the filters to the presence of EI in the 
final drug product: 
Filters are wildly used in many pharmaceutical process. In this particular case, there are three 
types of filters, but only the Polyvinyl Difluoride (PVDF) and Polypropylene (PP) contact with 
the drug products. After contact with the manufacturers they do not provide any results 
regarding to EI levels in filters. To obtain this information it was necessary to perform a 
literature, and the values obtained represent an overestimated scenario, as they result from 
extraction tests performed under more aggressive conditions than the product offers. 
The contribution of the filters to the presence of EI in final drug product is evaluated by 
comparing the sum of the contribution of household elemental impurity in each product. This 
sum is subsequently compared to parenteral PDE. 
 
3.4.5. Step 5: Evaluation of the contribution of the Water Treatment System to the 
presence of EI in the final drug product: 
Water is a very common element in most pharmaceutical preparations and easily 
contaminated. In the case of eye drops solutions, this element is the one that presents the 
highest percentage in its constitution and it is therefore essential to guarantee its quality. 
Therefore, it is essential that the pharmaceutical industries have a water treatment system. 
This system must be properly investigated and all equipment and materials that contact the 
water throughout the process must be identified to obtain sources of contamination. 
After this process, it was decided to contact the suppliers of each identified material, but there 
was no data about the presence of elemental impurities that could migrate to the drug. It was 
then necessary to conduct a research to obtain the extraction tests of these materials. The 
obtained concentrations represent a highly maximized scenario, however, it allows to obtain 
a maximized perspective of the system. 
 
3.4.6. Step 6: Evaluation of the contribution of the Container Closure System to the 
presence of EI in the final drug product: 
The packaging materials may be one of the major sources of EI in the final drug product, 
given the residence time of the product. In this particular case, the eye drops solution contact 
directly with Low Density Polyethylene (LDPE) since bottles are made by this polymer. To 
obtain the concentration of each elements that can leach into the drug product it is extremely 
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important to obtain the extraction test. The supplier provided the results of the USP Chapter 
<661> tests, which, although not including the concentration of all the elements, allows a 
more realistic view of the elements under test. After that, the concentrations were obtained, 
were compared to the PDEs of the route of administration. 
 
3.4.7. Step 7: Summary of the Risk Assessment: 
For summary of the Risk Assessment: 
• The predicted max contribution for each EI is the highest value observed in all 
components included in the Risk Assessment. 
• The predicted max contribution for each EI is the sum of the contribution of each 
component included in the Risk Assessment. 
• The predicted max contribution for each EI is the sum of each component of the Risk 
Assessment which hasn’t considered negligible. 
These scenarios were tested using a model table (Table 4), which gives a perspective of the 
total contribution of each elemental impurity in the final product. Thus, if the total contribution 
exceeds 30% of the parenteral PDE, it will be necessary to adopt control measures flowing 
the principles of the Risk Analysis in ICH Q9. 
 
Table 4. Model table that allows to obtain the Summary of the Risk Assessment. 
Element Class 
Presence/Risk 
Max 
predicted 
EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control 
Strategy 
Drug 
Substance 
and 
Excipients  
Manufacturing 
Equipment  
Filters  
Water 
Treatment 
System  
Container 
Closure 
System  
Cd 1         
Pb 1         
As 1         
Hg 1         
Co 2A         
V 2A         
Ni 2A         
…
 
…
 
        
        
        
 
 
 
 
 
 
26 
 
CHAPTER 4 – Results and Discussion of Results   
 
This chapter aims is to demonstrate the results obtained by applying the methodology 
described in chapter 3.4 Risk Assessment process. This methodology was applied to 3 
ophthalmologic products and will be presented in detail in this chapter. 
 
 
4.1. Drug product 1 
 
 
4.1.1. Drug product presentation 
Drug product 1 is to be administrated topically (ophthalmologic) in patients to reduce 
intraocular pressure in patients with glaucoma or ocular hypertension. It is formulated with 
one active substance a selective alpha2-adrenergic receptor agonist (45). 
Drug product 1 is presented as eye drops solution being available in packs of 1 dropper bottle 
of 5 or 10 ml, or 3 bottles of 5 ml. The bottles are made of low density polyethylene (LDPE) 
and are equipped with LDPE dropper dispenser. To seal the bottles uses a high-density 
polyethylene (HDPE) caps. The eye drop solution is in direct contact with LDPE bottle and 
occasionally with the LDPE drop dispenser. 
The usual dose of this eye drop solution is one drop in the affected eye(s) twice daily 
approximately every 12 hours. To be effective, drug product 1 should be administered every 
day.  
In Risk Assessment is essential to determine the Drug Product Maximum Daily Dose (MDD) 
and to perform this it is necessary to obtain the volume of a single drop of drug product. The 
drop size of an eye drop solution delivered from plastic dropper bottles depends by three 
major factors: the design and characteristics of the dropper tip and bottle, the physiochemical 
properties of the solution to be dispensed, and the patient´s manner of handling the dripper 
bottle. So, according the literature, the volume of an eye drop may vary from 25 to 70µl (in 
average 40µl) (46)(47)(48).  In the case of Laboratório Edol - Produtos Farmacêuticos, S.A.  the 
drop size was determined according to the methodology described in chapter 1151 of USP 
37. The Maximum Daily Dose of drug product 1 was determining by Equation 5 and take in 
consideration that each drop of drug product 1 has a medium volume of 34.13 µl and 
considering that are applied 4 drops per day (according to the SPC the maximum application 
is one drop every 12 hours in each eye). 
 
𝑀𝐷𝐷 = 𝑑𝑟𝑜𝑝 𝑠𝑖𝑧𝑒 ×  𝑑𝑜𝑠𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (Eq.5) 
 
Assuming the previously mentioned scenario, was obtained an MDD of 0.13 g. Table 5 shows 
the quantitative/qualitative composition of drug product 1 and the MDD of each component 
of drug product.   
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Table 5.Composition of drug product 1. 
Ingredients Quantity mg/ml 
Quantity 
% 
Amount per 
MDD (g) 
Function 
Excipient 1  13.86 0.1386 0.0018 
Stabilizing agent and 
humectant agent 
Excipient 2 68.32 0.6832 0.0089 Tonicity agent 
Excipient 3 4.65 0.0465 0.0006 Buffering system 
Excipient 4 0.48 0.0048 0.00006 Buffering system 
Excipient 5 0.01 0.0001 0.000001 Preservative 
API 1 2.0 0.02 0.00026 API 
Highly purified water Enough for 130L  - - Vehicle 
May contain hydrochloric acid 1M or 
sodium hydroxide 1M 
As need to pH 
6.5 – 7.6 
- - Adjustment agent 
 
4.1.1.1. Methodology used to perform the Risk Assessment 
The methodology implemented to carry out the Risk Assessment to drug product 1 is shown 
in (Appendix 2). In this methodology the blue arrows represent the chosen options to make 
the evaluation of the contribution of each EI. There is still, in two stages of this methodology, 
orange squares that allow to identify the places where both paths have been chosen. There 
are also steps in this flowchart, which are marked with "*" in red. This symbol allows to identify 
the critical places of this methodology, that is, places where the decisions taken can lead to 
different results of the Risk Assessment. It is important to mention that in the last stage of the 
Risk Assessment, Summary of the Risk Assessment, if any elementary impurity exceeds 
30% of the Parenteral PDE, control actions should be taken, using risk analysis and the 
principles described in ICH Q8 and Q9, however, these actions are already out of the goal of 
this scientific project. This methodology will be implemented in detail in the following sub-
chapters. 
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4.1.2. Information about components of the drug product to be included in the Risk 
Assessment 
 
 
4.1.2.1. API 1 
API 1 is an active substance used in formulation of API 1. This drug substance is provided by 
Farmark, S.A.  
The approved and qualified supplier do not provide any analytical results regarding elemental 
impurities levels in API 1. Thus, to perform a Risk Evaluation, it was assumed the worst-case, 
the concentration of the elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the 
permitted concentration of elemental impurities described in ICH Q3D. 
 
4.1.2.2. Excipient 1   
 
Excipient 1 is manufactured synthetically and provided by JOSE MANUEL GOMES SANTOS, 
LDA. The manufacturer of this excipient has provided a declaration about the origin of this 
product but has not yet provided the analytical results regarding the elemental impurities in this 
raw material.  
To perform a Risk Evaluation, it was assumed the worst-case, the concentration of the 
elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted concentration 
of elemental impurities described in ICH Q3D.  
 
4.1.2.3. Excipient 2 
Excipient 2 is synthetically manufactured material, provided by Merck Millipore. (Germany). 
Manufactured provided a basic dossier (in line with Module 3 CTD Format – Quality) and an 
Operational Excellence Dossier, concerning Excipient 2suitable for use as excipient 
EMPROVE® exp Ph.Eur., BP, USP.  
Operational Excellence dossier provides information regarding ICH Q3D on elemental 
impurities in Excipient 2. Such document, presents information on intentionally added 
elemental impurities during the manufacturing process and an elemental impurity scree, to 
provide analytical data regarding potentially present Class 1,2 and 3 elements.  The 
manufacturer states “No elements listed in class 1-3 according to the ICH Q3D are used in the 
manufacturing steps outlined in the manufacturing procedure”. 
The manufacture has provided the analytical results of potential present of elemental 
impurities. The results were obtained by ICP-MS in three commercial batches, as 
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recommended in ICH Q3D. In Table 6 only the results concerning class 1, 2A and some of 
class 3 (Li, SB and Cu) are under assessment, analytical results for class 2B will not be 
present. 
 
Table 6. Analytical data of elemental impurities in excipient 2, provided by Novo Nordisk Pharmatech. 
 
4.1.2.4. Excipient 3 
Excipient 3 is a manufactured synthetically and provided by JOSE MANUEL GOMES 
SANTOS, LDA. 
Manufacturer has not yet provided analytical results regarding elemental impurities level in 
Excipient 3.  
To perform a Risk Evaluation, it was assumed the worst-case, the concentration of the 
elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted concentration 
of elemental impurities described in ICH Q3D.  
 
4.1.2.5. Excipient 4 
Excipient 4 is a synthetically manufactured material, provided by JOSE MANUEL GOMES 
SANTOS, LDA. Manufacturer has provided a statement of concerning Excipient 4 (USP, BP, 
JP and Ph.Eur.) pharma grade. 
Manufacturer has not provided any analytical results regarding elemental impurities level on 
this excipient.  To perform a Risk Evaluation, it was assumed the worst-case, the concentration 
of the elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted 
concentration of elemental impurities described in ICH Q3D.  
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4.1.2.6. Excipient 5 
Excipient 5 is a preservative used to prevent decomposition by microbial growth or by 
undesirable chemical changes. This raw material is manufactured by chemical synthesis 
product. Manufacturer has provided a basic dossier demonstrating that this product can be 
used as an excipient.  
The manufacturer had provided additionally the analytical results regarding the potentially 
present of elemental impurities, take in consideration the principals described in ICH Q3D and 
USP Chapter <232>. In Table 7 only the results concerning class 1, 2A and some of class 3 
(Li, SB and Cu) are under assessment, analytical results for class 2B will not be present. 
This excipient is manufactured in accordance with the cGMP Guideline ICH Q7 for Active 
Pharmaceutical Ingredients and it is analysed according to the current European 
Pharmacopoeia (Ph.Eur.) and United States Pharmacopoeia (USP/NF). 
. 
Table 7.Analytical data of elemental impurities in Excipient 5, provided by Merck Millipore.
 
 
4.1.2.7. Highly Purified Water 
Highly purified water is a major component used in formulation of drug product 1. This excipient 
is manufactured in EDOL and is manufactured in a GMP certified manufacturing site.   
The highly purified water is obtained through reverse osmosis from drinking water complying 
the DL 306/2007 of August 27th, with changes introduced by DL 152/2017 of December 7, and 
it include controls among others, the level of some elemental impurities, like Arsenic (As), 
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Cadmium (Cd), Lead (Pb), copper (Cu), Chromium (Cr), Mercury (Hg) and Nickel (Ni). The 
quality of the water obtained through this process is “Highly purified water” and complies with 
the “Note for guidance on quality of water for pharmaceutical use CPMP/QWP/158/01 
revision)” and with the current Ph.Eur. monograph entitled “Highly Purified Water”. The water 
production system and treatment system will be addressed in section 4.1.8 Risk Assessment 
to Water treatment system. 
Considering the previous facts, the risk associated to this source is not significant and the 
predicted levels of elemental impurities contribution in drug product are expected to be 
negligible. For this reason, “Highly Purified Water” will not take in to consideration in the 
remining Risk Assessment. 
 
 
4.1.3. Sources of Contamination 
The ICH Q3D guideline for EI proposes the potential sources of EI during the manufacturing 
of a drug product. Each of these potential sources may contribute EI to the drug product, 
individually or through any combination. Figure 10 depicts the potential sources of EI that may 
be found in the drug product 1. During the Risk Assessment, the potential contributions from 
each of these sources will be considered to determine the overall contribution of elemental 
impurities to the final product.   
 
 
Figure 10. Potential sources of Elemental Impurities in drug product 1. 
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4.1.4. Elements included in Risk Assessment 
Concerning the ICH Q3D recommendations, the elements included in this Risk Assessment 
are the elements of Class 1, Class 2A and required Class 3 elements, and additionally some 
other elements intentionally added are included in this Risk Assessment (Table 8).  
Table 8. Elements considered in elemental impurities Risk Assessment for drug product 1.
 
 
4.1.5. Risk Assessment to Active Substance and Excipients 
The analysis of the contribution of the active substance and excipients to the presence of EI in 
the final product will be carried out following the principles described in ICH Q3D, however we 
will test the calculation options 1, 2A and 2B. Calculation option 3 will not be tested because it 
requires analysis of the final product. 
 
4.1.5.1. Option 1: Common permitted concentration limits of elements across 
drug product components for drug products with daily intakes not more than 
10 g:  
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The CL was obtained take in consideration the previous three daily amounts of drug product 
(3, 5 and 10 g/day). These simulations allow to obtain a perspective of these dosages to 
estimate the contribution of the active substance and excipients. The results are depicted 
respectively in Table 9, 10 and 11.  To have drug product acceptance by this option the 
predicted level for each component and each elemental impurity cannot be equal or superior 
to the calculated concentration limit. 
 
Table 9. Predicted Elemental impurities level in drug product 1 take in consideration the option 1 and assuming one daily 
amount of drug product of 3 g/day. 
Components API 1 Excipient 1  Excipient 2 Excipient 3 Excipient 4 Excipient 5 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.06 0.2 0.2 0.02 
Pb 0.5 0.5 0.15 0.5 0.5 0.04 
As 1.5 1.5 0.45 1.5 1.5 0.03 
Hg 0.3 0.3 0.09 0.3 0.3 0.4 
Co 0.5 0.5 0.15 0.5 0.5 0.02 
V 1 1 0.3 1 1 0.20 
Ni 2 2 0.6 2 2 0.10 
Li 25 25 7.5 25 25 0.05 
Sb 9 9 2.7 9 9 0.03 
Cu 30 30 9 30 30 0.08 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0.88 2.19 6.48 1.69 2.2 4.5 8.7 107.6 167.8 129.1 
Concentration 
limit (µg/g) 
0.67 1.67 5 1 1.67 3.33 6.67 83.3 30 100 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
 
Table 10. Predicted Elemental impurities level in drug product 1 take in consideration the option 1 and assuming one daily 
amount of drug product of 5 g/day. 
Components API 1 Excipient 1  Excipient 2 Excipient 3 Excipient 4 Excipient 5 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.06 0.2 0.02 0.2 
Pb 0.5 0.5 0.15 0.5 0.04 0.5 
As 1.5 1.5 0.45 1.5 0.03 1.5 
Hg 0.3 0.3 0.09 0.3 0.4 0.3 
Co 0.5 0.5 0.15 0.5 0.02 0.5 
V 1 1 0.3 1 0.20 1 
Ni 2 2 0.6 2 0.10 2 
Li 25 25 7.5 25 0.05 25 
Sb 9 9 2.7 9 0.03 9 
Cu 30 30 9 30 0.08 30 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0.88 2.19 6.48 1.69 2.17 4.5 8.7 107.55 167.81 129.08 
Concentration 
limit (µg/g) 
0.4 1 3 0.6 1 2 4 50 18 60 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
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Table 11. Predicted Elemental impurities level in drug product 1 take in consideration the option 1 and assuming one daily 
amount of drug product of 10 g/day. 
 
It is possible conclude that the adjustment of the daily dose of drug product was not sufficient 
to obtain the acceptance of this option. This fact can be justified by the worst-case assumed 
that originated lowers CL when compared with the total EI contribution. It is important to note 
that the concentrations of each component are also overestimated so that the total value may 
be higher than the real value. When compared with the PDE, in all cases, the total EI 
contribution is lower than the PDE. 
 
4.1.5.2. Option 2A: Common permitted concentration limits across drug product 
components for drug products with a specific daily intake:  
Maximum Daily Dose (MDD) of drug product 1 is 0.13 g. Acceptance criteria for this option is 
similar to option 1 thus, the predicted level of elemental impurities for each component and 
each elemental impurity cannot be equal or superior to the calculated concentration limit.  
 
 
 
 
 
 
Components API 1 Excipient 1  Excipient 2 Excipient 3 Excipient 4 Excipient 5 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.06 0.2 0.02 0.2 
Pb 0.5 0.5 0.15 0.5 0.04 0.5 
As 1.5 1.5 0.45 1.5 0.03 1.5 
Hg 0.3 0.3 0.09 0.3 0.4 0.3 
Co 0.5 0.5 0.15 0.5 0.02 0.5 
V 1 1 0.3 1 0.20 1 
Ni 2 2 0.6 2 0.10 2 
Li 25 25 7.5 25 0.05 25 
Sb 9 9 2.7 9 0.03 9 
Cu 30 30 9 30 0.08 30 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0.88 2.19 6.48 1.69 2.17 4.5 8.7 107.55 167.81 129.08 
Concentration 
limit (µg/g) 
0.2 0.5 1.5 0.3 0.5 1 2 25 9 30 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
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Table 12. Predicted Elemental impurities level in drug product 1 take in consideration the option 2A. 
Components API 1 Excipient 1 Excipient 2 Excipient 3 Excipient 4 Excipient 5 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.06 0.2 0.02 0.2 
Pb 0.5 0.5 0.15 0.5 0.04 0.5 
As 1.5 1.5 0.45 1.5 0.03 1.5 
Hg 0.3 0.3 0.09 0.3 0.4 0.3 
Co 0.5 0.5 0.15 0.5 0.02 0.5 
V 1 1 0.3 1 0.20 1 
Ni 2 2 0.6 2 0.10 2 
Li 25 25 7.5 25 0.05 25 
Sb 9 9 2.7 9 0.03 9 
Cu 30 30 9 30 0.08 30 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0.88 2.19 6.48 1.69 2.17 4.5 8.7 107.55 167.81 129.08 
Concentration 
limit (µg/g) 
15.4 38.5 115.4 23.1 115.4 76.9 153.8 1923.1 69.2 2307.7 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance YES YES YES YES YES YES YES YES YES YES 
 
After analysis the previous table it is possible conclude that all components in a drug product 
do not exceed the option 2A CL so, these elements can be used in any proportion in the drug 
product. When the total EI contribution is compared with the PDE, it is possible verify that the 
values obtained are a bit far to the parental PDE. For this product, the applicant can be use 
this option to validate the level of EI in components of drug product.   
 
4.1.5.3. Option 2B: Permitted concentration limits in individual components of a 
product with a specified daily intake:  
In option 2B are considered the quantitative composition of the drug product considering the 
MDD of that specific product.  
This option requires the determination of the MDD for each component and each element. To 
do this, we should multiply the predicted elemental impurities concentration value for the 
correspondent component daily dose (obtained by multiplying drug product MDD for the weight 
of the corresponding excipient). 
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Table 13. Predicted Elemental impurities level take in consideration the option 2B. 
Components: API 1 Excipient 1  Excipient 2 Excipient 3 Excipient 4 Excipient 5 
Batch Formula 
(mg/ml): 
2.0 13.86 68.32 4.65 0.48 0.01 
MDD (g/day): 0.00026 0.0018 0.0089 0.0006 0.00006 0.000001 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.06 0.2 0.2 0.02 
Pb 0.5 0.5 0.15 0.5 0.5 0.04 
As 1.5 1.5 0.45 1.5 1.5 0.03 
Hg 0.3 0.3 0.09 0.3 0.3 0.4 
Co 0.5 0.5 0.15 0.5 0.5 0.02 
V 1 1 0.3 1 1 0.20 
Ni 2 2 0.6 2 2 0.10 
Li 25 25 7.5 25 25 0.05 
Sb 9 19 2.7 9 19 0.03 
Cu 30 30 9 30 30 0.08 
M
a
x
 d
a
il
y
 c
o
n
tr
ib
u
ti
o
n
 
fr
o
m
 e
x
c
ip
ie
n
t 
(µ
g
/d
a
y
) 
Cd 0,000052 0,00036 0,000534 0,00012 0,00000002 0,000012 
Pb 0,00013 0,0009 0,001335 0,0003 0,00000004 0,00003 
As 0,00039 0,0027 0,004005 0,0009 0,00000003 0,00009 
Hg 0,000078 0,00054 0,000801 0,00018 0,0000004 0,000018 
Co 0,00013 0,0009 0,001335 0,0003 0,00000002 0,00003 
V 0,00026 0,0018 0,00267 0,0006 0,0000002 0,00006 
Ni 0,00052 0,0036 0,00534 0,0012 0,0000001 0,00012 
Li 0,0065 0,045 0,06675 0,015 0,00000005 0,0015 
Sb 0,00234 0,0342 0,02403 0,0054 0,00000003 0,00054 
Cu 0,0078 0,054 0,0801 0,018 0,00000008 0,0018 
Total EI 
contribution 
(µg/day) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0,001 0,0027 0,008 0,002 0,003 0,005 0,011 0,135 0,067 0,162 
Control 
threshold 30% 
PDE (µg/day) 
0.6 1.5 4.5 0.9 1.5 3 6 75 27 90 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance YES YES YES YES YES YES YES YES YES YES 
The option 2B, according to the information provided by Table 13, is an approach valid to 
estimate the contribution of Active Substance and Excipients to presence of EI in final product. 
The daily contribution of each EI is very low, although the worse scenario has been assumed. 
 
4.2. Drug product 2 
 
 
4.2.1. Drug product presentation 
Drug product 2 is an eye drops solution that has 10 mg/ml of the API 2. This drug belongs to 
the pharmacotherapeutic group 15.3.2 - Medications used in ocular conditions; mydriatic and 
cycloplegic; anticholinergics. 
Drug product 2 is an anticholinergic that blocks muscarinic acetylcholine receptors, causing 
paralysis of the circular muscle of the iris and ciliary muscle. This blockage leads to pupil 
dilation and accommodation paralysis. 
This product is intended to be administrated topically for conducting examinations of the fundus 
of the eye, examinations of refraction and as mydriatic in the treatment of iritis, iridocyclites, 
choroidites and uveitis. 
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Drug product 2 is presented in a sterile LDPE bottle equipped with a LDPE dropper dispenser 
and to seal the bottle is used a HDPE cap. In term of exposure, the solution directly contacts 
with the LDPE bottle and occasionally with the dropper dispenser. Each bottle contains 5 ml 
of clear and colourless solution.  
The recommended dosage depends on its therapeutic indication, so cycloplegic refraction 
should be given one drop of drug product 2 (adults), followed by another drop five minutes 
later. In ophthalmology, this medicinal product should be administered in the same manner as 
for cycloplegic refraction. In case of Uveitis, a drop should be given 3 to 4 times a day.  
In Risk Assessment is essential to determine the Drug Product Maximum Daily Dose (MDD) 
and to perform this it is necessary to obtain the volume of a single drop of drug product.  
The drop size of an ophthalmologic drug product delivered from plastic dropper bottles 
depends by three factors like the design and characteristics of the dropper tip and bottle, the 
physiochemical properties of the solution, and the patient´s manner of handling the dripper 
bottle (46)(47)(49). Therefore, to obtain the drop size the drug manufacturer was performed tests 
according to the USP 37 Chapter 1151. According to the results obtained by each operator we 
considering that each drop has a medium volume of 31.54 µl, so considering that each drop of 
drug product 2 has a medium volume of 31.54 µl and the number of drops applied per day are 
3 and 4, the MDD for drug product 2, assuming that the patient is performing a two-eye 
treatment.  
The MDD obtained is 0.25 (0.03154x(2x4) and according this, the maximum daily amount for 
the active substance and the respective excipients used in the formulation of this 
pharmaceutical form, was calculated and the respective results are in the Table 14. 
Table 14. Qualitative/quantitative composition of drug product 2. 
Ingredients Quantity mg/ml Quantity % Amount per MDD (g) Function 
Excipient 6 7.5 0.075 0.00188 Buffering agent 
Excipient 7 4.5 0.045 0.00113 Buffering agent 
Excipient 8 0.6 0.006 0.00015 Buffer chelating agent 
Excipient 9 0.02 0.0002 0.000005 Buffering agent 
Excipient 5 0.2 0.002 0.00005 Preservative 
Excipient 2 
As needed to 300 
– 400 mOsm/Kg 
- - 
Osmolarity adjustment 
agent 
API 2 10 0.1 0.0025 API 
Highly purified water Enough for 150 l   -  Vehicle 
May contain hydrochloric acid 
1M or sodium hydroxide 1M 
As need to pH 3.0 
– 5.5 
- - Adjustment agent 
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4.2.1.1. Methodology used to perform the Risk Assessment 
The methodology implemented to carry out the Risk Assessment to drug product 2 eye drops 
solution is shown in (Appendix 2). In this methodology the blue arrows represent the chosen 
options to make the evaluation of the contribution of each EI. There is still, in two stages of this 
methodology, orange squares that allow to identify the places where both paths have been 
chosen. There are also steps in this flowchart, which are marked with "*" in red. This symbol 
allows to identify the critical places of this methodology, that is, places where the decisions 
taken can lead to different results of the Risk Assessment. It is important to mention that in the 
last stage of the Risk Assessment, Summary of the Risk Assessment, if any elementary 
impurity exceeds 30% of the Parenteral PDE, control actions should be taken, using risk 
analysis and the principles described in ICH Q8 and Q9, however, these actions are already 
out of the goal of this scientific project, so it was decided to finish this methodology as shown 
in (Appendix 2).This methodology will be implemented in detail in the following sub-chapters. 
 
 
4.2.2. Information about components of the drug product to be included in the Risk 
Assessment 
4.2.2.1. API 2 
API 2 is manufactured by UQUIFA SPAIN, SA, but after contact with this supplier he does not 
provide any information about the tests performed to evaluate the presence of elemental 
impurities in their products.  
To perform a Risk Evaluation, it was assumed the worst-case, the concentration of the 
elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted concentration 
of elemental impurities described in ICH Q3D.  
 
4.2.2.2. Excipient 5 
The information on this excipient is described in section 4.1.2.6 of this scientific project. 
 
4.2.2.3. Excipient 6 
Excipient 6 is used in formulation of drug product 2 as a buffering agent. This product is 
manufactured by PANREAC and after contact with this manufacturer he does not provide any 
analytical results regarding elemental impurities levels on Excipient 6.  
To perform a Risk Evaluation, it was assumed the worst-case, the concentration of the 
elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted concentration 
of elemental impurities described in ICH Q3D. 
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4.2.2.4. Excipient 7  
Excipient 7 is a buffering agent used in the formulation of drug product 2. This product is 
synthetically and provided by VWR INTERNACIONAL, LDA. Manufactured provided the basic 
dossier, concerning Excipient 7 suitable for the biopharmaceutical production EMPROVE® bio 
Ph.Eur, BP, USP.  
After contact with this supplier he does not provide any information about the tests performed 
to evaluate the presence of elemental impurities in their products, so to perform a Risk 
Evaluation, it was assumed the worst-case, the concentration of the elements of Class 1, 2B 
and some of class 3 (Li, Sb and Cu) are the permitted concentration of elemental impurities 
described in ICH Q3D.  
4.2.2.5. Excipient 8 
Excipient 8 is synthetically manufactured material, provided by Merck Millipore. This excipient 
is used in the formulation as a Buffer chelating agent in very lower amounts.   
After contact with this manufacturer he does not provide any analytical results regarding 
elemental impurities levels on Excipient 8. So, to perform a Risk Evaluation, it was assumed 
the worst-case, the concentration of the elements of Class 1, 2B and some of class 3 (Li, Sb 
and Cu) are the permitted concentration of elemental impurities described in ICH Q3D.   
 
4.2.2.6. Excipient 9 
Excipient 9 is synthetically manufactured material, provided by PANREAC and after contact 
with the manufacturer 3V SIGMA USA, he informs it can be expected traces of heavy metals 
(as Co, Ni, Mo, Cr), but the metals are technically unavoidable in the manufacturing process 
and are not intentionally added during the manufacturing process. This manufactured does not 
provide any analytical results regarding elemental impurities levels on Excipient 9.  
To perform a Risk Evaluation, it was assumed the worst-case, the concentration of the 
elements of Class 1, 2B and some of class 3 (Li, Sb and Cu) are the permitted concentration 
of elemental impurities described in ICH Q3D. 
 
4.2.2.7. Excipient 2 
 
The information on this excipient is described in section 4.1.2.3 of this scientific project. 
 
4.2.2.8. Highly Purified Water 
The information on this excipient is described in section 4.1.2.7 of this scientific project. 
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4.2.3. Sources of Contamination 
The ICH Q3D guideline for EI proposes the potential sources of EI during the manufacturing 
of a drug product. Each of these potential sources may contribute EI to the drug product, 
individually or through any combination. Figure 12 depicts the potential sources of EI that may 
be found in the drug product 2. During the Risk Assessment, the potential contributions from 
each of these sources will be considered to determine the overall contribution of elemental 
impurities to the drug product.  
 
 
Figure 11. Potential sources of Elemental Impurities in drug product 2. 
 
4.2.4. Elements included in Risk Assessment 
ICH Q3D provide recommendations for inclusion of elemental impurities in the risk 
assessment, due this, the elements considered for this Risk Assessment are based on the 
recommendation of the ICH Q3D. In this respect, the elements included are these elements of 
Class 1, Class 2A and required Class 3 elements, and additionally some other elements 
intentionally added are added in Table 15.  
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Table 15. Elements considered in elemental impurities Risk Assessment for drug product 2.
 
4.2.5. Risk Assessment to Active Substance and Excipients 
The analysis of the contribution of the active substance and excipients to the presence of EI in 
the final product will be carried out following the principles described in ICH Q3D, however we 
will test the calculation options 1, 2A and 2B. Calculation option 3 will not be tested because it 
requires analysis of the final product. 
4.2.5.1. Option 1: Common permitted concentration limits of elements across 
drug product components for drug products with daily intakes not more than 
10 g:  
Previously, in the in chapter of methodology, the CL was obtained assuming three daily 
amounts of drug product (3, 5 and 10 g/day). The results of this simulations are depicted 
respectively in Tables 16, 17 and 18. In order to have drug product acceptance by this option 
the predicted level for each component and each elemental impurity cannot be equal or 
superior to the calculated concentration limit. 
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Table 16. Predicted Elemental impurities level in drug product 2 take in consideration the option 1 and assuming one 
daily amount of drug product of 3 g/day. 
Components API 2 Excipient 6 Excipient 7 Excipient 8 Excipient 9 Excipient 5 Excipient 2 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.2 0.2 0.2 0.02 0.06 
Pb 0.5 0.5 0.5 0.5 0.5 0.04 0.15 
As 1.5 1.5 1.5 1.5 1.5 0.03 0.45 
Hg 0.3 0.3 0.3 0.3 0.3 0.4 0.09 
Co 0.5 0.5 0.5 0.5 0.5 0.02 0.15 
V 1 1 1 1 1 0.20 0.3 
Ni 2 2 2 2 2 0.10 0.6 
Li 25 25 25 25 25 0.05 7.5 
Sb 9 9 9 9 9 0.03 2.7 
Cu 30 30 30 30 30 0.08 9 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
1.08 2.69 7.98 1.99 2.67 5.5 10.7 132.6 47.73 159.1 
Concentration 
limit (µg/g) 
0.67 1.67 5 1 1.67 3.33 6.67 83.3 30 100 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
 
 
Table 17.Predicted Elemental impurities level in drug product 2 take in consideration the option 1 and assuming one daily 
amount of drug product of 5 g/day. 
Components API 2 Excipient 6 Excipient 7 Excipient 8 Excipient 9 Excipient 5 Excipient 2 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.2 0.2 0.2 0.02 0.06 
Pb 0.5 0.5 0.5 0.5 0.5 0.04 0.15 
As 1.5 1.5 1.5 1.5 1.5 0.03 0.45 
Hg 0.3 0.3 0.3 0.3 0.3 0.4 0.09 
Co 0.5 0.5 0.5 0.5 0.5 0.02 0.15 
V 1 1 1 1 1 0.20 0.3 
Ni 2 2 2 2 2 0.10 0.6 
Li 25 25 25 25 25 0.05 7.5 
Sb 9 9 9 9 9 0.03 2.7 
Cu 30 30 30 30 30 0.08 9 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
1.08 2.69 7.98 1.99 2.67 5.5 10.7 132.6 47.73 159.1 
Concentration 
limit (µg/g) 
0.4 1 3 0.6 1 2 4 50 18 60 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
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Table 18. Predicted Elemental impurities level in drug product 2 take in consideration the option 1 and assuming one 
daily amount of drug product of 10 g/day. 
Components API 2 Excipient 6 Excipient 7 Excipient 8 Excipient 9 Excipient 5 Excipient 2 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.2 0.2 0.2 0.02 0.06 
Pb 0.5 0.5 0.5 0.5 0.5 0.04 0.15 
As 1.5 1.5 1.5 1.5 1.5 0.03 0.45 
Hg 0.3 0.3 0.3 0.3 0.3 0.4 0.09 
Co 0.5 0.5 0.5 0.5 0.5 0.02 0.15 
V 1 1 1 1 1 0.20 0.3 
Ni 2 2 2 2 2 0.10 0.6 
Li 25 25 25 25 25 0.05 7.5 
Sb 9 9 9 9 9 0.03 2.7 
Cu 30 30 30 30 30 0.08 9 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
1.08 2.69 7.98 1.99 2.67 5.5 10.7 132.6 47.73 159.1 
Concentration 
limit (µg/g) 
0.2 0.5 1.5 0.3 0.5 1 2 25 9 30 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance No No No No No No No No No No 
As seen in the previous tables, none of the daily intake of drug products tested was approved. 
This fact can be explained by the assumed conditions, since these are overestimated and 
beyond that the daily doses are much higher than the reality. Therefore, this option is not the 
best to obtain the contribution of EI from Active Substance and Excipients.  
 
4.2.5.2. Option 2A: Common permitted concentration limits across drug product 
components for drug products with a specific daily intake:  
Option 2A is similar to option 1 since it also considers that all components in the formulation 
contribute with the same elemental impurities amount to drug product total elemental impurity 
level. Distinguishing these two options is the fact that Option 2A considers that actual MDD of 
the drug product. The MDD of drug product 2 is 0.25 g.  
Acceptance criteria for this option is similar to option 1 thus, the predicted level of elemental 
impurities for each component and each elemental impurity cannot be equal or superior to the 
calculated concentration limit.  
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Table 19.Predicted Elemental impurities level in drug product 2 take in consideration the option 2A. 
Components API 2 Excipient 6 Excipient 7 Excipient 8 Excipient 9 Excipient 5 Excipient 2 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.2 0.2 0.2 0.02 0.06 
Pb 0.5 0.5 0.5 0.5 0.5 0.04 0.15 
As 1.5 1.5 1.5 1.5 1.5 0.03 0.45 
Hg 0.3 0.3 0.3 0.3 0.3 0.4 0.09 
Co 0.5 0.5 0.5 0.5 0.5 0.02 0.15 
V 1 1 1 1 1 0.20 0.3 
Ni 2 2 2 2 2 0.10 0.6 
Li 25 25 25 25 25 0.05 7.5 
Sb 9 9 9 9 9 0.03 2.7 
Cu 30 30 30 30 30 0.08 9 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Cu 
1.08 2.69 7.98 1.99 2.67 5.5 10.7 132.55 47.73 159.1 
Concentration 
limit (µg/g) 
8 20 60 12 20 40 80 1000 360 1200 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance  YES YES YES YES YES YES YES YES YES YES 
 
After analysis the previous table it is possible conclude that all components in a drug product 
do not exceed the option 2A CL so, these elements can be used in any proportion in the drug 
product. When the total EI contribution is compared with the PDE, it is possible verify that the 
values obtained are a bit far to the parental PDE. For this product, the applicant can be use 
this option to validate the level of EI in components of drug product.   
 
4.2.5.3. Option 2B: Permitted concentration limits in individual components of a 
product with a specified daily intake:  
In option 2B are considered the quantitative composition of the drug product considering the 
Maximum Daily Dose of that specific product. This option requires the determination of the 
maximum daily dose for each component and each element. To do this, we should multiply the 
predicted elemental impurities concentration value for the correspondent component daily 
dose (obtained by multiplying drug product MDD for the weight of the corresponding excipient). 
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Table 20. Predicted Elemental impurities level of drug product 2 take in consideration the option 2B. 
Components: API 2 
Excipient 
6 
Excipient 7 
Excipient 
8 
Excipient 
9 
Excipient 5 
Excipient 
2 
Batch Formula 
(mg/ml): 
10 7.5 4.5 0.6 0.02 0.2 0.6 
MDD (1) (g/day): 0.0025 0.00188 0.00113 0.00015 0.000005 0.00005 0.00015 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) 
Cd 0.2 0.2 0.2 0.2 0.2 0.02 0.2 
Pb 0.5 0.5 0.5 0.5 0.5 0.04 0.5 
As 1.5 1.5 1.5 1.5 1.5 0.03 1.5 
Hg 0.3 0.3 0.3 0.3 0.3 0.4 0.3 
Co 0.5 0.5 0.5 0.5 0.5 0.02 0.5 
V 1 1 1 1 1 0.20 1 
Ni 2 2 2 2 2 0.10 2 
Li 25 25 25 25 25 0.05 25 
Sb 9 9 9 9 9 0.03 9 
Cu 30 30 30 30 30 0.08 30 
M
a
x
 d
a
il
y
 c
o
n
tr
ib
u
ti
o
n
 
fr
o
m
 e
x
c
ip
ie
n
t 
(µ
g
/d
a
y
) 
Cd 0.0005 0.000376 0.000226 0.00003 0.000001 0.000001 0.00003 
Pb 0.00125 0.00094 0.000565 0.000075 0.0000025 0.000002 0.000075 
As 0.00375 0.00282 0.001695 0.000225 0.0000075 0.0000015 0.000225 
Hg 0.00075 0.000564 0.000339 0.000045 0.0000015 0.00002 0.000045 
Co 0.00125 0.00094 0.000565 0.000075 0.0000025 0.000001 0.000075 
V 0.0025 0.00188 0.00113 0.00015 0.000005 0.00001 0.00015 
Ni 0.005 0.00376 0.00226 0.0003 0.00001 0.000005 0.0003 
Li 0.0625 0.047 0.02825 0.00375 0.000125 0.0000025 0.00375 
Sb 0.0225 0.01692 0.01017 0.00135 0.000045 0.0000015 0.00135 
Cu 0.075 0.0564 0.0339 0.0045 0.00015 0.000004 0.0045 
Total EI 
contribution 
(µg/day) 
Cd Pb As Hg Co V Ni Li Sb Cu 
0.001 0.003 0.009 0.002 0.003 0.006 0.012 0.145 0.052 0.174 
Control 
threshold 30% 
PDE (µg/day) 
0.6 1.5 4.5 0.9 1.5 3 6 75 27 90 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 300 
Acceptance  YES YES YES YES YES YES YES YES YES YES 
According to the information provided by Table 20, the option 2B for API 2 is valid to estimate 
the daily contribution of EI by Active Substance and Excipients. The total EI contribution 
obtained is very low when compared with control threshold 30% of parental PDE and much 
more when compared with the parental PDE. 
 
4.3. Drug Product 3 
 
4.3.1. Drug product presentation 
Drug product 3 is a product indicated to use in acute situations like conjunctivitis, blepharitis, 
dacryocystitis, corneal ulcers, trachoma and keratitis and are formulated in two pharmaceutical 
forms, in ointments and in eye drops solution. According the scope of this scientific project, the 
focus is on eye drops solution.    
This eye drops solution is formulated with one drug substance (a broad-spectrum antibiotic 
and marked antimicrobial activity, to be administrated topically (ophthalmologic) in patients. In 
the Table 21, are depicted the quantitative/qualitative composition of drug product 3 (50).  
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Drug product 3 is presented as a colorless, clear and odorless solution in a 10 ml sterile 
dropper bottle made of LDPE and each bottle contains 5ml of drug product. The bottle is 
equipped with LDPE dropper dispenser and to seal the dropper uses a HDPE cap. The eye 
drop solution is in direct contact with LDPE bottle and occasionally with the LDPE drop 
dispenser. 
In Risk Assessment is essential to determine the Drug Product MDD and to perform this it is 
necessary to obtain the volume of a single drop of drug product.  
The drop size of an ophthalmologic drug product delivered from plastic dropper bottles 
depends by three major factors: the design and characteristics of the dropper tip and bottle, 
the physiochemical properties of the solution to be dispensed, and the patient´s manner of 
handling the dripper bottle. So, according the literature, the volume of an eye drop may vary 
from 25 to 70µl (in average 40µl) (46)(47)(48). To obtain the correct drop size the drug 
manufacturer was realized tests according to USP 37, chapter 1151. This test revealed that 
the drop size of the product is approximately 32.25 µl. So, to determine the MDD  of drug 
product 3 was considered that each drop has a medium volume of 35.25 µl and the number of 
drops applied per day are 32 (according to the SPC the maximum application is two drops 
every two hours, however it is considered that the patient will not apply the pharmaceutical 
from during the night (8 hours), thus the number of applications per day are 16, for both eyes). 
The MDD obtained is (0.03525x32) 1.13g.  
Table 21. Composition of drug product 3 per bottle with 5 ml of solution. 
Ingredients Quantity mg/ml Quantity % Amount per MDD (g) Function  
API 3 8.00 0.80 0.009 API 
Excipient 6 7.70 0.77 0.0087 Buffering system 
Excipient 10 1.00 0.10 0.001 Buffering system 
Excipient 2 3.50 0.35 0.00396 Tonicity agent 
Excipient 5 0.20 0,02 0.00023 Preservative 
Excipient 11 26.00 2.6 0.029 Stabilizing agent  
Highly purified water As need to 1.00  - - Vehicle 
May contain hydrochloric acid 
10% or sodium hydroxide 40% 
As need to pH 6.5 
– 7.6 
- 
- 
Adjustment agent 
 
4.3.1.1. Methodology used to perform the Risk Assessment 
The methodology implemented to carry out the Risk Assessment to drug product 3 is shown 
in (Appendix 2). In this methodology the blue arrows represent the chosen options to make 
the evaluation of the contribution of each EI. There is still, in two stages of this methodology, 
orange squares that allow to identify the places where both paths have been chosen. There 
are also steps in this flowchart, which are marked with "*" in red. This symbol allows to identify 
the critical places of this methodology, that is, places where the decisions taken can lead to 
different results of the Risk Assessment. It is important to mention that in the last stage of the 
Risk Assessment, Risk Summing, if any elementary impurity exceeds 30% of the Parenteral 
PDE, control actions should be taken, using risk analysis and the principles described in ICH 
Q8 and Q9, however, these actions are already out of the goal of this scientific project, so it 
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was decided to finish this methodology as shown in (Appendix 2).This methodology will be 
implemented in detail in the following sub-chapters. 
4.3.2. Information about components of the drug product to be included in the Risk 
Assessment 
4.3.2.1. API 3 
API 3 is an Active Substance manufactured at Química Sintética, S.A.  
The manufacturer has provided the analytical results of potentially present elemental impurities 
and had evaluate the different potential sources of elemental impurities as required by ICH 
Q3D. Analytical data was determined through ICP-MS in three commercial batches, as 
recommended by ICH Q3D. All concentrations obtained are presented in Table 22. It is 
important to refer that the manufacturer only assess class1, 2A and some class 3 elements 
(Mo and Cr). Therefore, for the other elements included in Class 3 (Li, Sb, Cu) we were 
assumed the higher concentration obtained in analytical results of manufacturer. 
 
Table 22. Analytical data of elemental impurities in API 3, provided by Química Sintética, S.A.
 
 
4.3.2.2. Excipient 6 
The information on this excipient is described in section 4.2.2.3 of this scientific project. 
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4.3.2.3. Excipient 10  
Excipient 10 is synthetically manufactured, provided by VWR INTERNATIONAL, LDA. 
Manufacturer has provided the a statement of compliance with ICH Q3D concerning Excipient 
10 suitable for use as excipient EMPROVE® exp Ph.Eur,, BP, NF. 
Manufacturer has not provided the analytical results regarding elemental impurities levels on 
Excipient 10. To perform a Risk Evaluation, it was assumed the worst-case, the concentration 
of the elements of Class 1, 2B and some of class 3 (Li, MO, Sb, Cu and Cr) are the permitted 
concentration of elemental impurities described in ICH Q3D. 
 
4.3.2.4. Excipient 2 
The information on this excipient is described in section 4.1.2.3 of this scientific project. 
 
4.3.2.5. Excipient 11 
Excipient 11 is a stabilizing agent using in formulation of drug product 3. This raw material is 
provided by WACKER CHEMIE AG.  
Manufacturer has not provided the analytical results regarding elemental impurities levels on 
Excipient 11. To perform a Risk Evaluation, it was assumed the worst-case, the concentration 
of the elements of Class 1, 2B and some of class 3 (Li, MO, Sb, Cu and Cr) are the permitted 
concentration of elemental impurities described in ICH Q3D. 
 
4.3.2.6. Excipient 5 
The information on this excipient is described in section 4.1.2.6 of this scientific project. 
 
4.3.2.7. Highly Purified Water 
The information on this excipient is described in section 4.1.2.7 of this scientific project. 
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4.3.3. Sources of Contamination 
The ICH Q3D guideline for EI proposes the potential sources of EI during the manufacturing 
of a drug product. Each of these potential sources may contribute EI to the drug product, 
individually or through any combination. Figure 14 depicts the potential sources of EI that may 
be found in the drug product drug product 3 eye drops solution. During the Risk Assessment, 
the potential contributions from each of these sources will be considered to determine the 
overall contribution of elemental impurities to the drug product.  
 
 
Figure 12. Potential sources of Elemental Impurities in drug product 3. 
 
4.3.4. Elements included in Risk Assessment 
ICH Q3D provide recommendations for inclusion of elemental impurities in the risk 
assessment, due this, the elements considered for this Risk Assessment are based on the 
recommendation of the ICH Q3D. In this respect, the elements included are these elements of 
Class 1, Class 2A and required Class 3 elements, and additionally some other elements 
intentionally added are added in this Risk Assessment in Table 23.  
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Table 23. Elements considered in elemental impurities Risk Assessment for drug product 3. 
 
 
4.3.5. Risk Assessment to Active Substance and Excipients 
The analysis of the contribution of the active substance and excipients to the presence of EI in 
the final product will be carried out following the principles described in ICH Q3D, however we 
will test the calculation options 1, 2A and 2B. Calculation option 3 will not be tested because it 
requires analysis of the final product. 
 
4.3.5.1. Option 1: Common permitted concentration limits of elements across 
drug product components for drug products with daily intakes not more than 
10 g:  
Option 1 takes into consideration that the MDD of drug product does not exceed 10 g/day. 
Also, it considers that all the components in the formulation contribute with the same elemental 
impurities amount to the drug product total concentration.  
Like we said previously in the in chapter of methodology, the concentration limit (CL) was 
obtained assuming three daily amounts of drug product (3, 5 and 10 g/day). The results of this 
simulations are depicted respectively in Tables 24, 25 and 26. In order to have drug product 
acceptance by this option the predicted level for each component and each elemental impurity 
cannot be equal or superior to the calculated concentration limit. 
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Table 24. Predicted Elemental impurities level in drug product 3 take in consideration the option 1 and assuming one daily 
amount of drug product of 3 g/day. 
Components API 3 Excipient 6 Excipient 10 Excipient 2 Excipient 5 Excipient 11 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) Cd 0.06 0.2 0.2 0.06 0.02 0.2 
Pb 0.15 0.5 0.5 0.15 0.04 0.5 
As 0.15 1.5 1.5 0.45 0.03 1.5 
Hg 0.9 0.3 0.3 0.09 0.4 0.3 
Co 0.15 0.5 0.5 0.15 0.02 0.5 
V 0.1 1 1 0.3 0.20 1 
Ni 2.5 2 2 0.6 0.10 2 
Li 2.5 25 25 7.5 0.05 25 
Sb 2.5 9 9 2.7 0.03 9 
Mo 0.3 30 30 9 0.08 30 
Cu 2.5 0.2 0.2 9 0.02 0.2 
Cr 0.8 0.5 0.5 9 0.04 0.5 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Mo Cu Cr 
0.74 1.84 5.13 2.29 1.82 3.6 9.2 85.1 32.2 99.4 12.1 11.3 
Concentration 
limit (µg/g) 
0.67 1.67 5 1 1.67 3.33 6.67 83.3 30 500 100 366.7 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 1500 300 1100 
Acceptance No No No No No No No No No Yes Yes Yes 
 
 
Table 25. Predicted Elemental impurities level in drug product 3 take in consideration the option 1 and assuming one daily 
amount of drug product of 5 g/day.  
Components API 3 Excipient 6 Excipient 10 Excipient 2 Excipient 5 Excipient 11 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) Cd 0.06 0.2 0.2 0.06 0.02 0.2 
Pb 0.15 0.5 0.5 0.15 0.04 0.5 
As 0.15 1.5 1.5 0.45 0.03 1.5 
Hg 0.9 0.3 0.3 0.09 0.4 0.3 
Co 0.15 0.5 0.5 0.15 0.02 0.5 
V 0.1 1 1 0.3 0.20 1 
Ni 2.5 2 2 0.6 0.10 2 
Li 2.5 25 25 7.5 0.05 25 
Sb 2.5 9 9 2.7 0.03 9 
Mo 0.3 30 30 9 0.08 30 
Cu 2.5 0.2 0.2 9 0.02 0.2 
Cr 0.8 0.5 0.5 9 0.04 0.5 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Mo Cu Cr 
0.74 1.84 5.13 2.29 1.82 3.6 9.2 85.1 32.2 99.4 12.1 11.3 
Concentration 
limit (µg/g) 
0.4 1 3 0.6 1 2 4 50 18 300 60 220 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 1500 300 1100 
Acceptance No No No No No No No No No Yes Yes Yes 
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Table 26. Predicted Elemental impurities level in drug product 3 take in consideration the option 1 and assuming one daily 
amount of drug product of 10 g/day. 
Components API 3 
Excipient 
6 
Excipient 
10 
Excipient 
2 
Excipient 5 Excipient 11 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) Cd 0.06 0.2 0.2 0.06 0.02 0.2 
Pb 0.15 0.5 0.5 0.15 0.04 0.5 
As 0.15 1.5 1.5 0.45 0.03 1.5 
Hg 0.9 0.3 0.3 0.09 0.4 0.3 
Co 0.15 0.5 0.5 0.15 0.02 0.5 
V 0.1 1 1 0.3 0.20 1 
Ni 2.5 2 2 0.6 0.10 2 
Li 2.5 25 25 7.5 0.05 25 
Sb 2.5 9 9 2.7 0.03 9 
Mo 0.3 30 30 9 0.08 30 
Cu 2.5 0.2 0.2 9 0.02 0.2 
Cr 0.8 0.5 0.5 9 0.04 0.5 
Total EI contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Mo Cu Cr 
0.74 1.84 5.13 2.29 1.82 3.6 9.2 85.1 32.2 99.4 12.1 11.3 
Concentration limit 
(µg/g) 
0.2 0.5 1.5 0.3 0.5 1 2 25 9 150 30 110 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 1500 300 1100 
Acceptance No No No No No No No No No Yes Yes Yes 
With the information provided in Tables 24, 25 and 26, it is possible to conclude that although 
daily doses are more adjusted to reality, they are still very overestimated for this drug product. 
In this simulation was included other elements. It is important to note that has obtained for 
three elements the acceptance, even these values represent the worst-case scenario, but 
following the principals described in ICH Q3D, to validate theses calculation options it is 
necessary that all elements had approval. Other calculation options available in the ICH Q3D 
will have to be tested. 
 
4.3.5.2. Option 2A: Common permitted concentration limits across drug product 
components for drug products with a specific daily intake:  
Option 2A is similar to option 1 since it also considers that all components in the formulation 
contribute with the same elemental impurities amount to drug product total elemental impurity 
level. Distinguishing these two options is the fact that Option 2A considers that actual MDD of 
the drug product. MDD obtained of drug product 3 is 1.13g consequently. 
Acceptance criteria for this option is similar to option 1 thus, the predicted level of elemental 
impurities for each component and each elemental impurity cannot be equal or superior to the 
calculated concentration limit.  
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Table 27. Predicted Elemental impurities level in drug product 3 take in consideration the option 2A. 
Components API 3 Excipient 6 Excipient 10 Excipient 2 Excipient 5 Excipient 11 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) Cd 0.06 0.2 0.2 0.06 0.02 0.2 
Pb 0.15 0.5 0.5 0.15 0.04 0.5 
As 0.15 1.5 1.5 0.45 0.03 1.5 
Hg 0.9 0.3 0.3 0.09 0.4 0.3 
Co 0.15 0.5 0.5 0.15 0.02 0.5 
V 0.1 1 1 0.3 0.20 1 
Ni 2.5 2 2 0.6 0.10 2 
Li 2.5 25 25 7.5 0.05 25 
Sb 2.5 9 9 2.7 0.03 9 
Mo 0.3 30 30 9 0.08 30 
Cu 2.5 0.2 0.2 9 0.02 0.2 
Cr 0.8 0.5 0.5 9 0.04 0.5 
Total EI 
contribution 
(µg/g) 
Cd Pb As Hg Co V Ni Li Sb Mo Cu Cr 
0.7 1.8 5.13 2.3 1.8 3.6 9.2 85.1 32.2 99.4 12.1 11.3 
Concentration 
limit (µg/g) 
1.8 4.4 13.04 2.7 4.4 8.9 17.7 221.2 79.6 1327.4 265.5 973.5 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 1500 300 1100 
Acceptance YES YES YES YES YES YES YES YES YES YES YES YES 
With the analysis of Table 27, it can be concluded that the total contribution of EI of each 
element is much lower than the CL obtained by equation 12, these elements can be used in 
any proportion in the drug product. This fact can be explained by the replacement of daily 
intake of drug product by a much more realistic scenario, MDD. Therefore, if the applicant 
could continue the risk analysis for the remaining sources of contamination, however, taking 
into account the objective of this scientific project we will continue the test of the calculation 
options for option 2B.  
 
4.3.5.3. Option 2B: Permitted concentration limits in individual components of a 
product with a specified daily intake:  
In option 2B are considered the quantitative composition of the drug product considering the 
Maximum Daily Dose of that specific product.  
This option requires the determination of the maximum daily dose for each component and 
each element. To do this, we should multiply the predicted elemental impurities concentration 
value for the correspondent component daily dose (obtained by multiplying drug product MDD 
for the weight of the corresponding excipient). 
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Table 28. Predicted Elemental impurities level in drug product 3 take in consideration the option 2B. 
Components: API 3 
Excipient 
6 
Excipient 10 Excipient 2 Excipient 11 Excipient 5 
Batch 
Formula 
(mg/ml): 
8.00 7.70 1.00 3.50 26.00 0.20 
MDD (1) 
(g/day): 
0.009 0.0087 0.001 0.00396 0.029 0.00023 
C
o
n
c
e
n
tr
a
ti
o
n
s
 o
f 
E
I 
(µ
g
/g
) Cd 0.06 0.2 0.2 0.06 0.2 0.02 
Pb 0.15 0.5 0.5 0.15 0.5 0.04 
As 0.15 1.5 1.5 0.45 1.5 0.03 
Hg 0.9 0.3 0.3 0.09 0.3 0.4 
Co 0.15 0.5 0.5 0.15 0.5 0.02 
V 0.1 1 1 0.3 1 0.20 
Ni 2.5 2 2 0.6 2 0.10 
Li 2.5 25 25 7.5 25 0.05 
Sb 2.5 9 9 2.7 9 0.03 
Mo 0.3 30 30 9 30 0.08 
Cu 2.5 0.2 0.2 9 0.2 0.02 
Cr 0.8 0.5 0.5 9 0.5 0.04 
M
a
x
 d
a
il
y
 c
o
n
tr
ib
u
ti
o
n
 
fr
o
m
 e
x
c
ip
ie
n
t 
(µ
g
/d
a
y
) 
Cd 0.00054 0.00174 0.0002 0.0002376 0.0058 0.0000046 
Pb 0.00135 0.00435 0.0005 0.000594 0.0145 0.0000092 
As 0.00135 0.01305 0.0015 0.001782 0.0435 0.0000069 
Hg 0.0081 0.00261 0.0003 0.0003564 0.0087 0.000092 
Co 0.00135 0.00435 0.0005 0.000594 0.0145 0.0000046 
V 0.0009 0.0087 0.001 0.001188 0.029 0.000046 
Ni 0.0225 0.0174 0.002 0.002376 0.058 0.000023 
Li 0.0225 0.2175 0.025 0.0297 0.725 0.0000115 
Sb 0.0225 0.0783 0.009 0.010692 0.261 0.0000069 
Mo 0.0027 0.261 0.03 0.03564 0.87 0.0000184 
Cu 0.0225 0.00174 0.0002 0.03564 0.0058 0.0000046 
Cr 0.0072 0.00435 0.0005 0.03564 0.0145 0.0000092 
Total EI 
contribution 
(µg/day) 
Cd Pb As Hg Co V Ni Li Sb Mo Cu Cr 
0.009 0.02 0.06 0.02 0.02 0.04 0.1 1.02 0.38 1.19 0.066 0.062 
Control 
threshold 30% 
PDE (µg/day) 
0.6 1.5 4.5 0.9 1.5 3 6 75 27 450 90 330 
PDE (µg/day) 2 5 15 3 5 10 20 250 90 1500 300 1100 
Acceptance  YES YES YES YES YES YES YES YES YES YES YES YES 
As shown in Table 28, the total daily contribution of each elemental impurities identified is 
much lower than the threshold 30% PDE control, which allows us to state that very large 
quantities would be necessary for this limit to be exceeded, although the obtained results 
represent a maximized scenario. The estimation of the contribution to presence of EI from 
Active Substance and Excipients used in formulation of API 3 eye drops solution can be 
obtained by option 2B. 
 
 
 
 
55 
 
4.3.6. Risk Assessment to Manufacturing Equipment 
In pharmaceutical industry most of equipment are made of stainless steel. There are different 
grades of stainless steel with a range of properties, but in pharmaceutical industry the main 
equipment are made by austenic stainless steel series (304, 304L, 316 and 316L) because 
they are highly corrosion resistant and not react with the active material or excipients used in 
pharmaceutical manufacturing (51). In Table 29, are presented the composition of grades 304, 
316 and 316L. 
 
Table 29. Composition of stainless steel grades 304, 316 and 316L. The values are present in percentage and represent 
the worst-case scenario. 
Material Class 1 Class 2A Class 3 Ref. 
 As Hg Pb Cd Co Ni V Li Sb Cu Mo Cr 
 
Stainless Steel 
304 
NP* NP* NP* NP* NP* 12% NP* NP NP* NP* NP* 20% (52) 
Stainless Steel 
316 
NP* NP* NP* NP* NP* 14% NP* NP NP* NP* 3% 18% (53) 
Stainless steel 
 316L 
NP* NP* NP* NP* NP* 14% NP* NP* NP* NP* 3 % 18% (53) 
*NP – Not present 
 
To realize the Risk Assessment for the manufacturing equipment, a study was carried out on 
the manufacturing process to identify the equipment that directly contact with the three drugs 
products. The identified equipment is organized in Table 30.  
 
Table 30. Main equipment that directly contact with the three drugs products during their manufacturing. 
Drug Product Equipment Brand Material 
API 1 
Reactor/Mixer Novinox 200L Stainless Steel 316L 
Reactor/Mixer 
SEITE-WERKE DB 110 A 
FW 
Stainless Steel 316L 
API 2 
Reactor/Mixer Progresso RAVS 200L Stainless Steel 316 
API 3 
All Filling and encapsulating IMA F57 Stainless Steel 316L 
After the identification of the equipment that directly contact the products under study, it can 
be verified that most of them consist of 316L stainless steel, except the tubing components of 
filling and encapsulating machine. This machine is composed with a silicone tubes that feed 
the glass nozzle that dispense the correct dosage in the bottle, but in terms of contribution of 
these compounds they are considered negligible, due the time of exposure. According this, 
to perform the risk assessment for manufacture equipment will only take into account the 
constitution of stainless steel. Therefore, and take in account the information provided in Table 
29 and 30, the composition of the stainless steel 316 and 316L is the same so, for the propose 
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of the risk assessment it was decided to assume the composition of the stainless steel 316L 
for all equipment. 
To obtain information about the level of presence EI in each manufacture equipment, the 
manufacturers was contacted, but they only provide the analytical the quality certificates,  
The Risk of EI contamination from stainless steel into the drug product during the 
manufacturing is raised from the passive layer, layer that forms on the surface of stainless 
steel and confers resistance to corrosion, not from the alloy substrate. This passive layer 
consists primarily of chromium oxides, hydroxides and iron compounds, which form on the 
outermost surface of the metal phase and the elements that may potentially leach into the drug 
product from passive layer are Cr, Fe, Mo and Ni (54). For the purpose of Risk Assessment 
was decided only include the elements that constitutes the stainless steel (Table 29), Cr, Mo 
and Ni, so these elements are considered intentionally added.   
The potential contribution of EI originating from 316L stainless steel was determined by a 
mathematical assay. To obtain this contribution was assumed a conservative approach, it was 
assumed 0.5 g/metal leaches from each produced batch to the finished drug product. This 
scenario was very overestimate in order to obtain an extreme scenario. This scenario was 
highly unlikely to happen in a GMP manufacturing site and leaching of 0.5 g/metal would be 
immediately detected by visual/cleaning inspection or by GMP control measures instituted. 
Furthermore, even 0.5 g of metal would leach from the stainless steel 316L equipment this 
concentration wouldn't have an impact in the finished drug product, calculations were done, to 
determine the level of elemental impurities derived from the stainless steel in the finished 
product. 
To obtain the amount of metal can leach per each gram of product it was decided to use the 
product that had the smaller batch, which would represent the most serious scenario. 
Therefore, the calculations were made for the API 1 with a batch size of 130L. Assuming an 
estimated loss of 0.5 gram of metal per batch, per gram of product we would have 3.8 µg of 
metal. 
It is possible to determine the corresponding concentration of Nickel, Molybdenum and 
Chromium per each gram of the finished drug product, considering stainless steel 316L 
material composition.  
 
  
 
 
 
 
Ni  Mo Cr 
 
14% 3% 18% 
 
 
 
 
Metal/ gram of product = 3.8 µg 
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Table 31. Stainless steel 316L EI contribution in the finished drug product considering material composition. 
Stainless 
Steel 
Elemental 
Impurity 
Calculation Concentration (µg/g) 
Parenteral PDE 
(µg/day) 
Acceptance 
316L 
Ni 3.8 µg × 0.14 0.53 20 Yes 
Mo 3.8 µg × 0.03 0.11 1500 Yes 
Cr 3.8 µg × 0.18 0.68 1100 Yes 
 
With the analysis of previous, we can conclude that the predicted concentration of elemental 
impurities in 316L stainless steel is much lower than the parental PDE, even though an 
extremely high metal concentration was assumed. Thus, an extra-large quantity of metal was 
necessary it was necessary to reach these limiting concentrations. The values obtained only 
reflects the amount of metal present in a gram of product so, if we considerate the MDD, the 
concentration of metals would be much lower than the value obtained. The concentration levels 
can be influenced by the time of residence of the solution in the equipment and by the 
manufacture conditions. According to the low residence times and the lack of any extremes of 
pH during the manufacture process we can conclude that the risk of elemental impurities 
inclusion from this source is very low. 
Moreover, all equipment’s are qualified and controlled by GMP’s controls and according to the 
ICH Q3D "Application of process knowledge, selection of equipment, equipment qualification 
and GMP's controls ensure a low contribution from manufacturing equipment". Thus, given the 
low concentration of elemental impurities potentially derived from the manufacturing 
equipment, equipment qualification and GMP controls, the outcome of this assessment is that 
the risk of EI inclusion from manufacturing equipment is negligible. 
 
4.3.7. Risk Assessment to Filters 
In the pharmaceutical industry it is very common to use sterilizing filters to remove all unwanted 
entities from the solution without their quality being affected (55)(56). During the manufacture of 
this three drug products, there is a sterilizing filtration stage before the solution is introduced 
into its primary packaging. In the sterilizing filtration there are two types of filters, polypropylene 
filter (PP) (Millipore Polygard CR filter) and polyvinylidene difluoride filter (PVDF) (Millipore 
Durapore Cartridge). Because they directly contact with the drug product can be a source of 
elemental impurities, so it is important to evaluate the level of elemental entities that may 
leachable and contaminate the drug product. In order to understand the elements that may be 
present in these materials, the supplier was contacted and informed that he was sensitized to 
this problematic, however, he did not carry out any evaluation of the presence of elemental 
impurities in the filters but it confirmed the absence of the elements included in class 1 of ICH 
Q3D, based on the information provided by the respective supplier. Nevertheless, a 
bibliographic search was performed to identify the main elements present in the filters. 
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These concentration levels, represent the amount of each elemental impurity that could be 
extracted under defined extraction condition. Alternatively, destructive testes, generally via 
digestion, can be used to quantify the level of this contaminants (3).  In most of the studies, 
strong acids/basis were used which, are still considerate very aggressive when compared with 
the conditions involved in drug product manufacturing. 
Table 32. Predicted EI levels from filters materials used in the manufacture train of the drug products, obtained through 
extraction. Concentrations are presented in µg/g. Data retrieved from reference (3)(57). 
NA* - Not Available; ND* - Not Detected  
According to the information provided in Table 32, we can verify that the obtained values are 
extremely lower when compared with the PDE’s, although the worse scenario has been 
assumed. Even so, the values obtained in the extractable tests may be overestimated because 
the conditions under which the tests are performed are much more aggressive than the solution 
properties. It is also considered that the time of exposure of the product to the filters is 
negligible since it is minimal. So, the potential for the filters to contaminate the drug product in 
significant amounts is extremely low and the predicted levels could be even lower if the 
maximum daily contribution had been obtained. Thus, we consider that the contribution of the 
filters to the presence of elemental impurities is negligible. 
 
Element 
PP (Polypropylene) 
(µg/g) 
PVDF 
(Polyvinylidene 
fluoride) (µg/g) 
Total 
contribution of 
EI (µg/g) 
Parenteral 
PDE (µg/day) 
Acceptance 
C
la
s
s
 1
 
Cd ≤0.01 - ≤0.01 2 Yes 
Pb ≤0.01 0.0003 ≤0.0103 5 Yes 
As ≤0.01 - ≤0.01 15 Yes 
Hg NA* - NA* 3 Yes 
C
la
s
s
 2
A
 
Co ≤0.01 0.0001 ≤0.0101 5 Yes 
V ≤0.01 - ≤0.01 10 Yes 
Ni ≤0.01 0.0005 ≤0.011 20 Yes 
C
la
s
s
 2
B
 
Se ≤0.01 - ≤0.01 80 Yes 
Ag ≤0.01 - ≤0.01 10 Yes 
C
la
s
s
 3
 
Li ≤0.01 - ≤0.01 250 Yes 
Sb ≤0.01 - ≤0.01 90 Yes 
Mo ≤0.01 ND* ≤0.01 1500 Yes 
Cu ≤0.01 0.0021 ≤0.0121 300 Yes 
Sn ≤0.01 0.0002 ≤0.0102 600 Yes 
Cr ≤1 0.0003 ≤1.0003 1100 Yes 
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4.3.8. Risk Assessment to Water treatment system  
Water is the most widely used substance, raw material or starting material in the production, 
processing and formulation of pharmaceutical products, so it is extremely important to control 
the level of contaminants by proper design of the system, periodic sanitization and by taking 
appropriate measures to prevent microbial proliferation. Thus, it is essential to study the entire 
water treatment system to identify which materials that directly contact with water and which 
may be potential contaminants of elemental impurities.  
Water used in the manufacturing process is “Highly Purified Water” (HPW) obtained through 
reverse osmosis and manufacturing in situ by EDOL.  In Figure 15, is shown a diagram of the 
process to obtain HPW. 
 
Figure 13. Diagram of the water treatment system. 
The water treatment system is constituted by pre-treatment system, a treatment system and a 
distribution line in the form of a loop in order to obtain highly purified water. The water pre-
treatment system subjects water from the public network throw a Millipore 
PREPACK/PROGARD particle filtering system, after this, the water is conducted by a PVC 
pipes to the treatment system. The treatment system consists of passing the pre-treated water 
through the units of reverse osmosis and eletrodeionization comprised of two units of Elix ® 
70 and 100, each one equipped with UV lamp installed. The produced water coming out of 
these units come in three interconnected storage and distribution tanks SDS 350.  All of these 
three tanks are equipped with a UV lamp for sanitization. In one of the distribution tanks there 
is a distribution pump to sending the water to the distribution loop. This line, ring-shaped, has 
an UV lamp, Durapore filter and a Durapore filter charged positively. After this filter there is a 
membrane valve, in clean area, to collect the highly purified water. The water returns to the 
three storage tanks after passing through another Durapore filter. Total Organic Carbon (TOC) 
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and the conductivity of the water distribution line is monitored on-line, using an analyser in-
line. 
The sanitization of the system is made whenever there is a growing trend in the level of 
microbial contamination but should be done at least once a year if the contamination levels are 
within specifications. In addition to the sanitization and maintenance, to guarantee the HPW 
quality, preventive physicochemical (appearance, oxidizing substances, nitrates, heavy 
metals, conductivity and total organic carbon (TOC)) and microbial analysis are also 
performed, in accordance with the European Pharmacopoeia (EP).   
The water used for cleaning /rinsing equipment, containers and closure, according to GMP 
and “Note for guidance on Quality of Water for Pharmaceutical use (CPMP/QWP/158/01 
revision)”, initial rinse for equipment, containers and closure should be purified water and in 
final rinse used for equipment, containers and closure should be the same quality of water 
used in the final stage of manufacture of the drug product.  
To obtain the Risk Assessment of Water Treatment System, was necessary identify all 
components of this system and the respective material that composes them. All material 
identified are organized in Table 33. It is important to note that after contact with the suppliers 
it was not possible to obtain the material that constitutes all the components identified and thus 
the risk analysis will be carried out with the identified materials. 
Table 33. Components of the water treatment system to be included in the Risk Assessment. 
Components Material 
Transfer tubes PVC 
Particle filter Millipore PREPACK/PROGARD TL1 NA* 
System Millipore Elix ® 70/ Elix ® 100 
Progard TL1filter NA* 
Pump NA* 
Reverse Osmosis Cartridge NA* 
Elix module NA* 
UV lamp Glass and Stainless Steel 316L 
Storage tank Millipore SDS 350 
UV lamp Glass and Stainless Steel 316L 
Tank NA* 
Pump of storage tanks Stainless steel 316L 
Circulation/pressurizing pump Gundfos/CHI 4-50 AW-BUBE Stainless steel 316L 
UV lamp in the ring Glass and Stainless steel 316L 
Sterilizing filter Millipore Durapore charged PVDF (Polyvinylidene fluoride) (58) 
Reservoi.r of Sodium Hypochlorite solution Polyethylene (PE) 
Dosing pump Milton Roy – LMI P553-398N3 PVC 
In-line analyser of TOC and Conductivity Sievers 500 RL0 NA* 
NA* - Not available  
The level of EI present in each component of this system was obtained by a literature, because 
after contact with their suppliers no answers were obtained regarding the level of this 
contaminants in each product. The research performed was focused on the type of material 
that constituted each component of the systems and the values obtained for most of the 
materials resulted from extraction tests carried out in conditions much more aggressive than 
the production of eye drops solution so, the values can be overestimated. In the case of 
stainless steel, which was widely used in this system, the worst-case scenario was assumed, 
which would be the leaching of 0.5 g of metal. The predicted elemental impurities levels from 
the water treatment system are shown in Table 34. 
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Table 34.Predicted EI levels from water treatment system material. Concentrations are presented in µg/g. Data retrieved from 
reference (53)(57)(3). 
NP* - Not Present; ND* - Not Detected  
 
After analysis of the Table 34, we can conclude that the predicted level of elemental impurities 
from the water treatment system are extremely low when compared with the PDE’s for 
parenteral route. The values obtained, like we said previously are overestimate, because the 
concentration of some materials is obtained by extractions conditions much more aggressive 
than the batch conditions and for some values the concentrations obtained are much lower 
than the values assumed.  In addition, if the maximum daily contribution of elemental impurities 
from water treatment system were obtained these values are much lower than the values 
obtained under extraction conditions.  The HPW complies with the Ph.Eur. monograph and 
specification and quality are continuously ensured at all points of use, through frequent 
analysis and its risk are controlled by GMP since validation and qualification of water 
purification, storage and distribution systems are fundamental part of GMP and form an integral 
part of GMP inspection. According to ICH Q3D the risk of inclusion of elemental impurities from 
water can be reduced by complying with compendial Ph.Eur. water quality requirements if 
purified water or water for injections is used in the manufacture process.  
Element 
PE 
(Polyethylene) 
(µg/g) (3) 
Stainless 
Steel 
316L 
(µg/g) 
(53) 
PVC 
(Polyvinyl 
Chloride) 
(µg/g) (3) 
PVDF 
(Polyvinylidene 
fluoride) (µg/g) 
(57) 
Glass  
(µg/g) 
(3) 
Total 
contribution 
of EI (µg/g) 
Parenteral 
PDE 
(µg/day) 
Acceptance 
C
la
s
s
 1
 
Cd ≤1 NP* ≤0.01 NP* NP* ≤1.01 2 Yes 
Pb ≤1 NP* NP* 0.0003 ≤1 ≤2.0003 5 Yes 
As ≤1 NP* ≤1 NP* ≤1 ≤3 15 Yes 
Hg NP* NP* ≤0.01 NP* NP* ≤0.01 3 Yes 
C
la
s
s
 2
A
 
Co 0.01 NP* ≤0.01 0.0001 NP* ≤0.0101 5 Yes 
V NP* NP* ≤1 NP* NP* ≤1 10 Yes 
Ni NP* 1.08 ≤1 0.0005 NP* ≤2.0805 20 Yes 
C
la
s
s
 2
B
 
Se ≤1 NP* ≤1 NP* NP* ≤2 80 Yes 
Ag ≤1 NP* NP* NP* NP* ≤1 10 Yes 
C
la
s
s
 3
 
Li ≤1 NP* NP* NP* NP* ≤1 250 Yes 
Sb ≤1 NP* ≤1 NP* NP* ≤2 90 Yes 
Mo NP* 0.20 ≤1 ND* NP* ≤1.20 1500 Yes 
Cu ≤1 NP* ≤1 0.0021 NP* ≤2.0021 300 Yes 
Sn ≤1 NP* NP* 0.0002 NP* ≤1.0002 600 Yes 
Cr ≤ 0.01 1.2 ≤0.01 0.0003 NP* ≤2.2103 1100 Yes 
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In conclusion, even though water is considered as a potential source of elemental impurities, 
the implemented control system ensues that the HPW complies with the EP specifications and 
therefore, predicted levels of elemental impurities contribution in drug product are expected to 
be negligible. For these reasons, water will not be taken into consideration, in the remining of 
the Risk Assessment.  
 
4.3.9. Risk Assessment to Container Closure System  
The container closure system used for the primary packaging consists of a Low Density 
Polyethylene (LDPE) Bottle with a LDPE dropper dispenser. The bottle is seal with a High 
Density Polyethylene (HDPE) cap. The plastics used in packaging and systems delivery must 
be suitable with for their intended use and adequately protect the pharmaceutical product over 
the product’s shelf-life and must be composed with materials that are safe to use, because 
some interactions between a plastic material and the pharmaceutical product, like sorption, 
uptake of product components by the plastic material, leaching, release of plastic material 
components to the product, can affect the quality of drug product  (59)(60).  
To evaluate the levels of elemental impurities that can leaching from the container closure 
system to the drug product, was contacted the manufacturer of the container closure system. 
He informed that he had contacted his suppliers and had been informed by the supplier of the 
resins that any elements included in class 1, 2, 3 listed in ICH Q3D are not intentionally added 
during the manufacture of resins. More inform, that the manufacturer of the Remafin white 
informs that the elements As, Cd, Pb, Hg, Cr, Cu, Ni, Ru, V, Sb, Ba, Co, Se and Sn have not 
ether intentionally added during its production. It is important to refer that all standard white 
products are tested to poof the compliance with the USP chapter <661> and EP chapter 
<3.1.5>. 
Risk Assessment was performed for the components of the container closure system which 
directly contacts with the drug product. Therefore, this was only done for LDPE since it is 
considered that the product is only in contact with the bottle and with the dropper dispenser. 
The elements included in this Risk Evaluation are those required by ICH Q3D guideline for 
parental route which assumed the values obtained by the USP chapter <661>.  In Table 35 
are presented the predicted elemental impurities levels from the LDPE bottle and dropper 
dispenser into drug product.  
Table 35. Predicted EI levels from LDPE bottle and dropper dispenser. Concentrations are presented in µg/g. 
Material Elemental Impurities Concentration of EI (µg/g) 
Parental PDE 
(µg/day) 
Acceptance 
Low Density 
Polyethylene (LDPE) 
Cd <0.2 2 Yes 
Pb <0.2 5 Yes 
As <0.2 15 Yes 
Hg <0.2 3 Yes 
Co - 5 - 
V - 10 - 
Ni - 20 - 
Li - 250 - 
Sb <0.2 90 Yes 
Cu <0.2 300 Yes 
It is important to refer that the concentration of elemental impurities obtained from USP <661> 
represent the amount of metals present in the LDPE plastic, so for the purposes of the Risk 
63 
 
Assessment it was assumed that the levels of elemental impurities obtained by USP <661> 
are totally leached to the drug product during it shelf-time. Even assuming this scenario, the 
concentration of elemental impurities is well below than the limiting concentrations. These 
values can be much lower if the maximum daily contribution of the LDPE were obtained. 
Therefore, we can affirm that the liberation from the packaging components represents an 
essentially low safety risk. Thus, taking into account the available results we can affirm that 
the contribution of the packaging components to the elemental impurities in eye drops solution 
is considered negligible. 
 
4.3.10.  Summary of the Risk Assessment 
In this summary of the Risk Assessment performed all relevant sources of potential EI have 
been identified and tested using a component approach with the scope to identify the 
contribution of each source to the presence of EI in final drug product. To do this, all information 
regarding to the EI levels is based on data provided by the manufacturers or based on data 
obtained to the scientific literature. It´s important to refer that in both cases the values obtained 
are overestimate, allowing to obtain an extreme scenario. To perform this summary of the Risk 
Assessment, was tested some approaches to get the best way to perform this Risk 
Assessment. Therefore, since the contribution of the Active Substance and Excipients that 
compound this drug product passed in calculation options 2A and 2B, three scenarios were 
tested for these two calculation options: 
• The predicted max contribution for each EI is the highest value observed in all 
components included in the Risk Assessment. 
• The predicted max contribution for each EI is the sum of the contribution of each 
component included in the Risk Assessment. 
• The predicted max contribution for each EI is the sum of each component of the Risk 
Assessment which hasn’t considered negligible. 
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4.3.10.1. Summary of Risk Assessment for drug product 1. 
 
Table 36. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g)  
Manufacturing 
Equipment 
(µg/g)  
Filters (µg/g) 
Water 
Treatment 
System (µg/g)  
Container Closure 
System (µg/g)  
Cd 1 0.88 No ≤ 0.01 ≤1.01 No ≤1.01 0.6 YES 
Pb 1 2.19 No ≤ 0.0103 ≤2.00 <0.2 ≤2.19 1.5 YES 
As 1 6.48 No ≤ 0.01 ≤3 <0.2 ≤6.48 4.5 
YES 
Hg 1 1.69 No NA* ≤0.01 <0.2 ≤1.69 0.9 
YES 
Co 2A 2.17 No ≤ 0.01 ≤0.01 No ≤2.17 1.5 
YES 
V 2A 4.5 No ≤ 0.01 ≤1 No ≤4.5 3 
YES 
Ni 2A 8.7 0.53 ≤ 0.011 ≤2.08 No ≤8.7 6 
YES 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 107.55 No ≤ 0.01 ≤1 No ≤107.5 75 
YES 
Sb 3 167.81 No ≤ 0.01 ≤2 <0.2 ≤167.8 27 
YES 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤1.20 450 No controls required 
Cu 3 129.08 No ≤ 0.012 ≤2.012 <0.2 ≤129.08 90 YES 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤1.00 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤2.21 330 No controls required 
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Table 37. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day)  
Manufacturing 
Equipment 
(µg/g)  
Filters (µg/g)  
Water 
Treatment 
System (µg/g)  
Container Closure 
System (µg/g) 
Cd 1 0.001 No ≤ 0.01 ≤1.01 No ≤1.01 0.6 YES 
Pb 1 0.0027 No ≤ 0.0103 ≤2.00 <0.2 ≤2.0 1.5 YES 
As 1 0.008 No ≤ 0.01 ≤3 <0.2 ≤3.00 4.5 No controls required 
Hg 1 0.002 No NA* ≤0.01 <0.2 ≤0.2 0.9 No controls required 
Co 2A 0.003 No ≤ 0.01 ≤0.01 No 0.02 1.5 No controls required 
V 2A 0.005 No ≤ 0.01 ≤1 No ≤1.00 3 No controls required 
Ni 2A 0.01 0.53 ≤ 0.011 ≤2.08 No ≤2.08 6 No controls required 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 0.135 No ≤ 0.01 ≤1 No ≤1.00 75 No controls required 
Sb 3 0.067 No ≤ 0.01 ≤2 <0.2 ≤2.00 27 No controls required 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤1.20 450 No controls required 
Cu 3 0.162 No ≤ 0.012 ≤2.012 <0.2 ≤2.00 90 No controls required 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤1.00 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤2.21 330 No controls required 
NA*- Not available   
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Table 38. Conclusion summary of EI Risk Assessment assuming the contribution of Active Substance and Excipients given by option 2A and all contribution given by all components of the 
Risk Assessment against the Control Threshold for each identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g) 
Manufacturing 
Equipment 
(µg/g) 
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 0.88 No ≤ 0.01 ≤1.01 No ≤ 1.9 0.6 YES 
Pb 1 2.19 No ≤ 0.0103 ≤2.00 <0.2 ≤ 4.4003 1.5 YES 
As 1 6.48 No ≤ 0.01 ≤3 <0.2 ≤ 9.49 4.5 YES 
Hg 1 1.69 No NA* ≤0.01 <0.2 ≤ 1.7 0.9 YES 
Co 2A 2.17 No ≤ 0.01 ≤0.01 No ≤ 2.19 1.5 YES 
V 2A 4.5 No ≤ 0.01 ≤1 No ≤ 5.51 3 YES 
Ni 2A 8.7 0.53 ≤ 0.011 ≤2.08 No ≤ 11.321 6 YES 
Se 2B No No ≤ 0.01 ≤2 No ≤ 2.01 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤ 1.21 3 No controls required 
Li 2B 107.55 No ≤ 0.01 ≤1 No ≤ 108.56 75 YES 
Sb 3 167.81 No ≤ 0.01 ≤2 <0.2 ≤ 170.02 27 YES 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤ 1.31 450 No controls required 
Cu 3 129.08 No ≤ 0.012 ≤2.012 <0.2 ≤130.1 90 YES 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤ 1.0104 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤ 2.89 330 No controls required 
NA*- Not available   
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Table 39.  Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g)  
Manufacturing 
Equipment 
(µg/g)  
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 0.88 No Negligible risk 
Negligible risk 
No 0.88 0.6 YES 
Pb 1 2.19 No Negligible risk 
Negligible risk 
Negligible risk 2.19 1.5 YES 
As 1 6.48 No Negligible risk Negligible risk Negligible risk 6.48 4.5 YES 
Hg 1 1.69 No NA* Negligible risk Negligible risk 1.69 0.9 YES 
Co 2A 2.17 No Negligible risk Negligible risk No 2.17 1.5 YES 
V 2A 4.5 No Negligible risk Negligible risk No 4.5 3 YES 
Ni 2A 8.7 Negligible risk Negligible risk Negligible risk No 8.7 6 YES 
Se 2B No No Negligible risk Negligible risk No - 130 - 
Ag 2B No No Negligible risk Negligible risk Negligible risk - 3 - 
Li 2B 107.55 No Negligible risk Negligible risk No 107.55 75 YES 
Sb 3 167.81 No Negligible risk Negligible risk Negligible risk 167.81 27 YES 
Mo 3 No 
Negligible risk Negligible risk Negligible risk 
No - 450 - 
Cu 3 129.08 No 
Negligible risk Negligible risk Negligible risk 
129.08 90 YES 
Sn 3 No No 
Negligible risk Negligible risk 
No - 180 - 
Cr 3 No 
Negligible risk Negligible risk Negligible risk 
No - 330 - 
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Table 40. Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/day) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day)  
Manufacturing 
Equipment  
Filters  
Water 
Treatment 
System  
Container Closure 
System  
Cd 1 0.008 No Negligible risk 
Negligible risk 
No 0.008 0.6 
No controls required 
Pb 1 0.02 No Negligible risk 
Negligible risk 
Negligible risk 0.02 1.5 
No controls required 
As 1 0.06 No Negligible risk Negligible risk Negligible risk 0.06 4.5 No controls required 
Hg 1 0.01 No NA* Negligible risk Negligible risk 0.01 0.9 No controls required 
Co 2A 0.02 No Negligible risk Negligible risk No 0.02 1.5 No controls required 
V 2A 0.04 No Negligible risk Negligible risk No 0.04 3 No controls required 
Ni 2A 0.08 Negligible risk Negligible risk Negligible risk No 0.08 6 No controls required 
Se 2B No No Negligible risk Negligible risk No - 130 - 
Ag 2B No No Negligible risk Negligible risk Negligible risk - 3 - 
Li 2B 1.0 No Negligible risk Negligible risk No 1.0 75 No controls required 
Sb 3 0.37 No Negligible risk Negligible risk Negligible risk 0.37 27 No controls required 
Mo 3 No 
Negligible risk Negligible risk Negligible risk 
No - 450 - 
Cu 3 1.25 No 
Negligible risk Negligible risk Negligible risk 
1.25 90 No controls required 
Sn 3 No No 
Negligible risk Negligible risk 
No - 180 - 
Cr 3 No 
Negligible risk Negligible risk Negligible risk 
No - 330 - 
NA*- Not available   
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4.3.10.2. Summary of Risk Assessment for drug product 2. 
 
Table 41. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A. 
NA*- Not available   
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g)   
Manufacturing 
Equipment 
(µg/g)   
Filters (µg/g)   
Water 
Treatment 
System (µg/g)   
Container Closure 
System (µg/g)   
Cd 1 1.08 No ≤ 0.01 ≤1.01 0.2 ≤1.08 0.6 YES 
Pb 1 2.69 No ≤ 0.0103 ≤2.00 <0.2 ≤2.69 1.5 YES 
As 1 7.98 No ≤ 0.01 ≤3 <0.2 ≤7.98 4.5 
YES 
Hg 1 1.99 No NA* ≤0.01 <0.2 ≤1.99 0.9 
YES 
Co 2A 2.67 No ≤ 0.01 ≤0.01 No ≤2.67 1.5 
YES 
V 2A 5.5 No ≤ 0.01 ≤1 No ≤5.5 3 
YES 
Ni 2A 10.7 0.53 ≤ 0.011 ≤2.08 No ≤10.7 6 
YES 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 132.55 No ≤ 0.01 ≤1 No ≤132.55 75 
YES 
Sb 3 47.73 No ≤ 0.01 ≤2 <0.2 ≤47.73 27 
YES 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤1.20 450 No controls required 
Cu 3 159.1 No ≤ 0.012 ≤2.012 <0.2 ≤159.1 90 YES 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤1.00 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤2.21 330 No controls required 
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Table 42. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day)   
Manufacturing 
Equipment 
(µg/g)   
Filters (µg/g)   
Water 
Treatment 
System (µg/g)   
Container Closure 
System (µg/g)   
Cd 1 0.001 No ≤ 0.01 ≤1.01 0.2 ≤1.01 0.6 YES 
Pb 1 0.003 No ≤ 0.0103 ≤2.00 <0.2 ≤2.0 1.5 YES 
As 1 0.009 No ≤ 0.01 ≤3 <0.2 ≤3.00 4.5 No controls required 
Hg 1 0.002 No NA* ≤0.01 <0.2 ≤0.2 0.9 No controls required 
Co 2A 0.003 No ≤ 0.01 ≤0.01 No ≤0.0101 1.5 No controls required 
V 2A 0.006 No ≤ 0.01 ≤1 No ≤1.00 3 No controls required 
Ni 2A 0.012 0.53 ≤ 0.011 ≤2.08 No ≤2.0805 6 No controls required 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 0.145 No ≤ 0.01 ≤1 No ≤1.00 75 No controls required 
Sb 3 0.052 No ≤ 0.01 ≤2 <0.2 ≤2.00 27 No controls required 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤1.20 450 No controls required 
Cu 3 0.174 No ≤ 0.012 ≤2.012 <0.2 ≤2.0021 90 No controls required 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤1.00 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤2.21 330 No controls required 
NA*- Not available   
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Table 43. Conclusion summary of EI Risk Assessment assuming the contribution of Active Substance and Excipients given by option 2A and all contribution given by all components of the 
Risk Assessment against the Control Threshold for each identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g)  
Manufacturing 
Equipment 
(µg/g) 
Filters (µg/g)  
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 1.08 No ≤ 0.01 ≤1.01 0.2 ≤2.3 0.6 YES 
Pb 1 2.69 No ≤ 0.0103 ≤2.00 <0.2 ≤7.0003 1.5 YES 
As 1 7.98 No ≤ 0.01 ≤3 <0.2 ≤11.19 4.5 YES 
Hg 1 1.99 No NA* ≤0.01 <0.2 ≤2.2 0.9 YES 
Co 2A 2.67 No ≤ 0.01 ≤0.01 No ≤2.69 1.5 YES 
V 2A 5.5 No ≤ 0.01 ≤1 No ≤6.51 3 YES 
Ni 2A 10.7 0.53 ≤ 0.011 ≤2.08 No ≤13.3 6 YES 
Se 2B No No ≤ 0.01 ≤2 No ≤2.01 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.21 3 No controls required 
Li 2B 132.55 No ≤ 0.01 ≤1 No ≤133.56 75 YES 
Sb 3 47.73 No ≤ 0.01 ≤2 <0.2 ≤49.94 27 YES 
Mo 3 No 0.11 ≤ 0.01 ≤1.20 No ≤1.32 450 No controls required 
Cu 3 159.1 No ≤ 0.012 ≤2.012 <0.2 ≤162.63 90 YES 
Sn 3 No No ≤ 0.0102 ≤1.0002 No ≤1.0104 180 No controls required 
Cr 3 No 0.68 ≤ 0.0003 ≤2.2103 No ≤2.81 330 No controls required 
NA*- Not available   
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Table 44. Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day)  
Manufacturing 
Equipment 
(µg/g)  
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 1.08 No 
Negligible risk Negligible risk Negligible risk 
1.08 0.6 YES 
Pb 1 2.69 No 
Negligible risk Negligible risk Negligible risk 
2.69 1.5 YES 
As 1 7.98 No 
Negligible risk Negligible risk Negligible risk 
7.98 4.5 
YES 
Hg 1 1.99 No NA* 
Negligible risk Negligible risk 
1.99 0.9 
YES 
Co 2A 2.67 No 
Negligible risk Negligible risk 
No 2.67 1.5 
YES 
V 2A 5.5 No 
Negligible risk Negligible risk 
No 5.5 3 
YES 
Ni 2A 10.7 Negligible risk 
Negligible risk Negligible risk 
No 10.7 6 
YES 
Se 2B No No 
Negligible risk Negligible risk 
No - 130 - 
Ag 2B No No 
Negligible risk Negligible risk 
Negligible risk - 3 - 
Li 2B 132.55 No 
Negligible risk Negligible risk 
No 132.55 75 
YES 
Sb 3 47.73 No 
Negligible risk Negligible risk 
Negligible risk 47.73 27 
YES 
Mo 3 No 
Negligible risk Negligible risk Negligible risk 
No - 450 - 
Cu 3 159.1 No 
Negligible risk Negligible risk 
Negligible risk 159.1 90 YES 
Sn 3 No No 
Negligible risk Negligible risk 
No - 180 - 
Cr 3 No 
Negligible risk Negligible risk Negligible risk 
No - 330 - 
NA*- Not available  
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Table 45. Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/day) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day)  
Manufacturing 
Equipment  
Filters  
Water 
Treatment 
System  
Container Closure 
System  
Cd 1 0.001 No Negligible risk 
Negligible risk Negligible risk 
0.001 0.6 No controls required 
Pb 1 0.003 No Negligible risk 
Negligible risk 
Negligible risk 0.003 1.5 No controls required 
As 1 0.009 No Negligible risk Negligible risk Negligible risk 0.009 4.5 No controls required 
Hg 1 0.002 No NA* Negligible risk Negligible risk 0.002 0.9 No controls required 
Co 2A 0.003 No Negligible risk Negligible risk No 0.003 1.5 No controls required 
V 2A 0.006 No Negligible risk Negligible risk No 0.006 3 No controls required 
Ni 2A 0.012 Negligible risk Negligible risk Negligible risk No 0.012 6 No controls required 
Se 2B No No Negligible risk Negligible risk No - 130 - 
Ag 2B No No Negligible risk Negligible risk Negligible risk - 3 - 
Li 2B 0.145 No Negligible risk Negligible risk No 0.145 75 No controls required 
Sb 3 0.052 No Negligible risk Negligible risk Negligible risk 0.052 27 No controls required 
Mo 3 No 
Negligible risk Negligible risk Negligible risk 
No - 450 - 
Cu 3 0.174 No 
Negligible risk Negligible risk Negligible risk 
0.174 90 No controls required 
Sn 3 No No 
Negligible risk Negligible risk 
No - 180 - 
Cr 3 No 
Negligible risk Negligible risk Negligible risk 
No - 330 - 
NA*- Not available     
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4.3.10.3. Summary of Risk Assessment for drug product 3. 
 
Table 46. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity. Contribution of drug substance and excipients by Option 2A. 
NA* - Not Available  
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy Drug Substance 
and Excipients 
Manufacturing 
Equipment 
Filters 
Water 
Treatment 
System 
Container Closure 
System 
Cd 1 0.7 No ≤ 0.01 ≤1.01 <0.2 ≤1.08 0.6 YES 
Pb 1 1.8 No ≤ 0.01 ≤2.00 <0.2 ≤2.0003 1.5 YES 
As 1 5.13 No ≤ 0.01 ≤3 <0.2 ≤5.13 4.5 YES 
Hg 1 2.3 No NA* ≤0.01 <0.2 ≤2.3 0.9 YES 
Co 2A 1.8 No ≤ 0.01 ≤0.01 No ≤1.8 1.5 YES 
V 2A 3.6 No ≤ 0.01 ≤1 No ≤3.6 3 YES 
Ni 2A 9.2 0.53 ≤ 0.01 ≤2.08 No ≤9.2 6 YES 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 85.1 No ≤ 0.01 ≤1 No ≤85.1 75 YES 
Sb 3 32.2 No ≤ 0.01 ≤2 <0.2 ≤32.2 27 YES 
Mo 3 99.4 0.11 ≤ 0.01 ≤1.20 No ≤99.4 450 No controls required 
Cu 3 12.1 No ≤ 0.01 ≤2.01 <0.2 ≤12.1 90 No controls required 
Sn 3 No No ≤ 0.01 ≤1.00 No ≤1.0002 180 No controls required 
Cr 3 11.3 0.68 ≤ 0.0003 ≤2.21 No ≤11.3 330 No controls required 
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Table 47. Conclusion summary of EI Risk Assessment assuming the highest value of each element observed in all Risk Assessment components against the Control Threshold for each 
identified elemental impurity.  Contribution of drug substance and excipients by Option 2B. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day) 
Manufacturing 
Equipment 
(µg/g) 
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 0.009 No ≤ 0.01 ≤1.01 <0.2 ≤1.01 0.6 YES 
Pb 1 0.02 No ≤ 0.01 ≤2.00 <0.2 ≤2.00 1.5 YES 
As 1 0.06 No ≤ 0.01 ≤3 <0.2 ≤3.00 4.5 No controls required 
Hg 1 0.02 No NA* ≤0.01 <0.2 ≤0.2 0.9 No controls required 
Co 2A 0.02 No ≤ 0.01 ≤0.01 No ≤0.02 1.5 No controls required 
V 2A 0.04 No ≤ 0.01 ≤1 No ≤1.00 3 No controls required 
Ni 2A 0.1 0.53 ≤ 0.01 ≤2.08 No ≤2.08 6 No controls required 
Se 2B No No ≤ 0.01 ≤2 No ≤2.00 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.00 3 No controls required 
Li 2B 1.02 No ≤ 0.01 ≤1 No ≤1.00 75 No controls required 
Sb 3 0.38 No ≤ 0.01 ≤2 <0.2 ≤2.00 27 No controls required 
Mo 3 1.19 0.11 ≤ 0.01 ≤1.20 No ≤1.20 450 No controls required 
Cu 3 0.07 No ≤ 0.01 ≤2.01 <0.2 ≤2.01 90 No controls required 
Sn 3 No No ≤ 0.01 ≤1.00 No ≤1.00 180 No controls required 
Cr 3 0.06 0.68 ≤ 0.0003 ≤2.21 No ≤2.21 330 No controls required 
NA*- Not available   
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Table 48. Conclusion summary of EI Risk Assessment assuming the contribution of Active Substance and Excipients given by option 2A and all contribution given by all components of the 
Risk Assessment against the Control Threshold for each identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
(µg/day) 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g) 
Manufacturing 
Equipment 
(µg/g) 
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 0.7 No ≤ 0.01 ≤1.01 <0.2 ≤1.92 0.6 YES 
Pb 1 1.8 No ≤ 0.01 ≤2.00 <0.2 ≤4.01 1.5 YES 
As 1 5.13 No ≤ 0.01 ≤3 <0.2 ≤8.34 4.5 YES 
Hg 1 2.3 No NA* ≤0.01 <0.2 ≤2.51 0.9 YES 
Co 2A 1.8 No ≤ 0.01 ≤0.01 No ≤1.82 1.5 YES 
V 2A 3.6 No ≤ 0.01 ≤1 No ≤4.61 3 YES 
Ni 2A 9.2 0.53 ≤ 0.01 ≤2.08 No ≤11.82 6 YES 
Se 2B No No ≤ 0.01 ≤2 No ≤2.01 130 No controls required 
Ag 2B No No ≤ 0.01 ≤1 <0.2 ≤1.21 3 No controls required 
Li 2B 85.1 No ≤ 0.01 ≤1 No ≤86.11 75 YES 
Sb 3 32.2 No ≤ 0.01 ≤2 <0.2 ≤34.41 27 YES 
Mo 3 99.4 0.11 ≤ 0.01 ≤1.20 No ≤100.72 450 No controls required 
Cu 3 12.1 No ≤ 0.01 ≤2.01 <0.2 ≤13.11 90 No controls required 
Sn 3 No No ≤ 0.01 ≤1.00 No ≤1.01 180 No controls required 
Cr 3 11.3 0.68 ≤ 0.0003 ≤2.21 No ≤14.19 330 No controls required 
NA*- Not available   
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Table 49.Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2A against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/g) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/g) 
Manufacturing 
Equipment 
(µg/g) 
Filters (µg/g) 
Water 
Treatment 
System (µg/g) 
Container Closure 
System (µg/g) 
Cd 1 0.7 No Negligible risk Negligible risk Negligible risk 0.7 0.6 YES 
Pb 1 1.8 No Negligible risk Negligible risk Negligible risk 1.8 1.5 YES 
As 1 5.13 No Negligible risk Negligible risk Negligible risk 5.13 4.5 YES 
Hg 1 2.3 No NA* Negligible risk Negligible risk 2.3 0.9 
YES 
Co 2A 1.8 No Negligible risk Negligible risk No 1.8 1.5 
YES 
V 2A 3.6 No Negligible risk Negligible risk No 3.6 3 
YES 
Ni 2A 9.2 Negligible risk Negligible risk Negligible risk No 9.3 6 
YES 
Se 2B No No Negligible risk Negligible risk No - 130 - 
Ag 2B No No Negligible risk Negligible risk Negligible risk - 3 - 
Li 2B 85.1 No Negligible risk Negligible risk No 85.1 75 
YES 
Sb 3 32.2 No Negligible risk Negligible risk Negligible risk 32.2 27 
YES 
Mo 3 99.4 Negligible risk Negligible risk Negligible risk No 99.4 450 No controls required 
Cu 3 12.1 No Negligible risk Negligible risk Negligible risk 12.1 90 No controls required 
Sn 3 No No Negligible risk Negligible risk No - 180 - 
Cr 3 11.3 Negligible risk Negligible risk Negligible risk No 11.3 330 No controls required 
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Table 50. Conclusion summary of EI Risk Assessment obtained only by the contribution of Active Substance and Excipients given by option 2B against the Control Threshold for each 
identified elemental impurity. 
Element Class 
Presence/Risk 
Max 
predicted EI 
exposure 
(µg/day) 
Control 
Threshold 
30% of 
Parental 
PDE 
Actions/Control Strategy 
Drug Substance 
and Excipients 
(µg/day) 
Manufacturing 
Equipment 
Filters 
Water 
Treatment 
System 
Container Closure 
System 
Cd 1 0.009 No Negligible risk Negligible risk Negligible risk 0.009 0.6 No controls required 
Pb 1 0.02 No Negligible risk Negligible risk Negligible risk 0.02 1.5 No controls required 
As 1 0.06 No Negligible risk Negligible risk Negligible risk 0.06 4.5 No controls required 
Hg 1 0.02 No NA* Negligible risk Negligible risk 0.02 0.9 No controls required 
Co 2A 0.02 No Negligible risk Negligible risk No 0.02 1.5 No controls required 
V 2A 0.04 No Negligible risk Negligible risk No 0.04 3 No controls required 
Ni 2A 0.1 Negligible risk Negligible risk Negligible risk No 0.1 6 No controls required 
Se 2B No No Negligible risk Negligible risk No - 130 - 
Ag 2B No No Negligible risk Negligible risk Negligible risk - 3 - 
Li 2B 1.02 No Negligible risk Negligible risk No 1.02 75 No controls required 
Sb 3 0.38 No Negligible risk Negligible risk Negligible risk 0.38 27 No controls required 
Mo 3 1.19 Negligible risk Negligible risk Negligible risk No 1.19 450 No controls required 
Cu 3 0.07 No Negligible risk Negligible risk Negligible risk 0.07 90 No controls required 
Sn 3 No No Negligible risk Negligible risk No - 180 - 
Cr 3 0.06 Negligible risk Negligible risk Negligible risk No 0.06 330 No controls required 
NA*- Not available   
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4.3.11. Discussion of Results 
In this chapter we intend to discuss all the results obtained through the implementation of the 
methodology presented in the section: "4.1.1.1 Methodology used to perform the Risk 
Assessment". 
As previously mentioned during this scientific project, the lack of information negatively 
conditioned the results obtained, since the concentrations assumed for the elements that did 
not have information are maximized. This factor may be at the origin of the reprobation of the 
calculation option 1 in the evaluation of the contribution of the active substance and excipients. 
In the remaining options, 2A and 2B, the approval was obtained, although in option 2A the 
concentrations are inferior to the obtained CLs. 
Regarding the contribution of the other sources of elemental impurities identified, it is important 
to mention that the list of materials that come into contact with the product could be more 
exhaustive, however, due to the difficulty in obtaining information of the constitution of each 
equipment, it was decided to assuming a simplified scenario taking the worst-case scenario. 
This scenario resulting in very high EI concentrations. Nevertheless, these levels were below 
the parenteral PDE, leading to their approval and consequently, following the principles 
described in ICH Q3D, excluded from the Risk Assessment. However, in this scientific project 
several scenarios were studied to obtain the summary of the Risk Assessment. 
The approaches under study are described in the section "4.1.10 Summary of the Risk 
Assessment" and the results obtained are organized in tables. In the first approach (Tables 
36, 41 and 46) are presented the result of the Risk Assessment from assuming the maximum 
concentration of each EI obtained from all possible sources of contamination. It was assumed 
either that the contribution of the active substance and excipients is given by the calculation 
option 2A. With the analysis of this table, we can verify that for most EI, it is necessary to adopt 
control actions, since they exceed 30% of the parenteral PDE. For all products, this problem 
can be justified with the high concentration values obtained by calculation option 2A, although 
the concentrations of each impurity are below the CL obtained. This high concentrations values 
are related with the overestimated scenario used to estimate the contribution of each 
compound. On the other hand, the results obtained by assuming the daily contribution of each 
elemental impurity (Tables 36, 42 and 47) are really, most EI had approval and control actions 
are not required, only for Cd and Pb. 
In Tables 38, 43 and 48 are the results obtained from the sum of the contribution of all the 
sources considered in the Risk Assessment. It should be noted that this study was only 
possible for the calculation option 2A, since the contributions of each component were 
expressed in µg/g and in option 2B the results are in µg/day. Therefore, this scenario is unlikely 
to happen, because most of EI exceed the control threshold 30% of the parental PDE and 
consequently additional measures needs to be applied to control the levels of EI in final drug 
product. It is important to note that this result can be affected by the assumptions that a very 
high amount of the EI migrate to the drug product, since the extractions tests obtained by 
bibliographic search are carried out under much more aggressive conditions of extraction when 
compared with the conditions of the drug product.  
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The third approach consists of excluding all potential considered negligible of the Risk 
Assessment and the others are sum to obtain the max EI contribution, the application of this 
approach are placed in Tables 39, 40, 44, 45, 49 and 50. Comparing the results of this two 
tables it is possible to verify that the best results are obtained with option 2B, where all EI have 
acceptance.   
Thus, in view of the results obtained previously, the best way to obtain the Risk assessment is 
to choose the third approach conjugated with the 2B calculation option. However, it is believed 
that possibly the second approach would work with 2B calculation option only if the daily 
contribution of all the participants in the Risk Assessment had been obtained.   
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CHAPTER 5 – Conclusion 
With this research it was possible to verify that EI are commonly present in most of the 
materials that directly contact with the drug product and may affect the efficacy of the drug and 
the health of the patient. 
The lack of data is a great constraint for the realization of the Risk Assessment, as it is verified 
in the present scientific project in which it was necessary to recourse to bibliographical 
research to assume the worst case, since the data obtained from extractables corresponded 
to conditions much more aggressive than those offered by the product itself during its 
production. 
It has also been verified that the three test products, despite being used in quite different 
dosage regimens, are quite similar in terms of raw materials used in their production, 
manufacture train and packaging systems. Therefore, the methodologies applied, and the 
results obtained are similar, so there is no relationship between the mode of administration of 
the drug and the presence of EI. 
This guide presents some limitations in particular in identifying the sources of elemental 
impurities, where people and methods can have some impact, and in calculating options. 
During the simulation of the calculation options, that in all the products none obtained approval 
in option 1. In this scientific project it was tried to readjust the daily dose of drug product taking 
into account the typologies of existing systems of amazement however, taking into account the 
results obtained these still represent rather overrated scenario. Therefore, it would be 
advisable to readjust this formula for more adequate values, taking into account the route of 
administration and the pharmaceutical form.  
Based on the results obtained, it is concluded that the best calculation option to estimate the 
contribution of Active Substance and Excipients will be 2B, however this option implies the 
daily quantification of the contribution of each of the sources, which is a challenge given the 
scarcity of data. 
Concluding, we can affirm that in the present scientific project it presents an adequate 
methodology for the quantification of EI in the final product, however, in view of the condition 
presented previously, a very maximized approach is obtained. Given these facts and in the 
presence of more adequate EI values, it is possible to affirm that the results obtained would 
be very different in all the approaches assumed during this project. 
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CHAPTER 6 – Further Considerations  
In order to have continuity of the present project, it would be interesting to explore the best 
calculation option obtained in this project (2B) since for this to happen it is necessary to obtain 
the daily amounts that each of the possible sources of contamination contributes. 
It would still be interesting to apply the QRM principles, as described in ICH Q9. 
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Appendix 1 
 
According to the database provided by Infarmed, we obtained this circular diagram that 
allows us to obtain the most common types of bottles for eye drops solution. 
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Appendix 2 – Risk Assessment Methodology  
 
 
Drug product 
Identification of the 
sources of EI *
Search of EI in 
Active Substance 
and Excipients *
They are 
inttentionally 
added?
Perform the risk 
assessment with all  
elements
Consider in the risk 
assessment  the 
elements of table  
5.1 for respective 
route of 
administration 
No
Yes
Elements 
considered in Risk 
Assessment 
Apply the option 1 
of ICH Q3D 
Apply the option 2A
Search EI in Water 
treatment system * 
Search EI in 
Container closure 
systems *
Apply the option 2B
Search EI in 
manufacture 
equipment *
Study all 
manufacture 
process 
Supplier 
information 
available?*
Assume the Worst-
case scenario 
No
Yes
[EI]  CL obtained? *
Yes
No
[EI]  CL obtained? * No
Yes
Option excluded
Option excluded
[EI]   Control 
threshold 30% PDE? 
*
End of Risk 
Assessment
Yes
No
[EI]   Parental PDE? 
*
Significant 
Contribution
Negligible 
contribution 
Yes No
Search EI in Filters *  
[EI]   Parental PDE? 
* 
Significant 
Contribution
Negligible 
contribution 
Yes No
[EI]   Parental PDE? 
*
Significant 
Contribution
Negligible 
contribution 
Yes No
[EI]   Parental PDE? 
*
Significant 
Contribution
Negligible 
contribution 
Yes No
Summary of the Risk 
Assessment
The contribution of each EI 
are equal, or greater than, 
the 30% Parental PDE ?*
Control actions are 
required
Non control action 
are requiered
Yes No
End
1.
2.
 
Decision taken  
Steps of the Risk Assessment 
* 
Critical points  
Risk Assessment Legend:  
